Role of the Human Cytomegalovirus IE2 Protein on Transcriptional Regulation of Viral Promoters by Harris, Siabhon Michelle
Old Dominion University
ODU Digital Commons
Theses and Dissertations in Biomedical Sciences College of Sciences
Spring 2009
Role of the Human Cytomegalovirus IE2 Protein
on Transcriptional Regulation of Viral Promoters
Siabhon Michelle Harris
Old Dominion University
Follow this and additional works at: https://digitalcommons.odu.edu/biomedicalsciences_etds
Part of the Molecular Biology Commons, and the Virology Commons
This Dissertation is brought to you for free and open access by the College of Sciences at ODU Digital Commons. It has been accepted for inclusion in
Theses and Dissertations in Biomedical Sciences by an authorized administrator of ODU Digital Commons. For more information, please contact
digitalcommons@odu.edu.
Recommended Citation
Harris, Siabhon M.. "Role of the Human Cytomegalovirus IE2 Protein on Transcriptional Regulation of Viral Promoters" (2009).
Doctor of Philosophy (PhD), dissertation, , Old Dominion University, DOI: 10.25777/kzx1-8q27
https://digitalcommons.odu.edu/biomedicalsciences_etds/37
ROLE OF THE HUMAN CYTOMEGALOVIRUS IE2 PROTEIN ON 
TRANSCRIPTIONAL REGULATION OF VIRAL PROMOTERS 
by 
Siabhon Michelle Harris 
B.S. May 2002, North Carolina State University 
A Dissertation Submitted to the Faculty of 
Eastern Virginia Medical School and 
Old Dominion University in Partial Fulfillment of the 
Requirement for the Degree of 
DOCTOR OF PHILOSOPHY 
BIOMEDICAL SCIENCES 
EASTERN VIRGINIA MEDICAL SCHOOL 
OLD DOMINION UNIVERSITY 
May 2009 
Approved by: 
lie Kerry (Director) 
Ann Campbell (Member) 
ichard Drake (Member) 
Laura Hanson (Member) 
ABSTRACT 
ROLE OF THE HUMAN CYTOMEGALOVIRUS IE2 PROTEIN IN 
TRANSCRIPTIONAL REGULATION OF VIRAL PROMOTERS 
Siabhon Michelle Harris 
Eastern Virginia Medical School and 
Old Dominion University, 2009 
Director: Dr. Julie Kerry 
Human cytomegalovirus (HCMV) is a ubiquitous pathogen able to cause severe 
mortality and morbidity in immuno-compromised individuals. Successful infection by 
HCMV is dependent on expression of viral genes essential for replication. Immediate 
early (IE) gene products are the first subset of viral genes to be expressed during 
infection and function as key transcriptional regulators. IE2 is one the most 
predominantly expressed IE proteins and is essential for HCMV infection. IE2 
transactivates several viral promoters, including those of the essential viral DNA 
polymerase (UL54) and UL112-113 gene regions. IE2 is also able to autoregulate is own 
expression and repress expression of the major IE gene products. This study aims to 
investigate the role of IE2 and cellular proteins in regulation of viral promoters in order 
to gain a better understanding of early events required for HCMV replication. Through 
the use of both transient assays and complementing assays in recombinant HCMV clones, 
we show that single amino acid mutations in the C-terminus of IE2 impair both IE2-
mediated transactivation of early gene promoters and autorepression of the major IE 
promoter. These mutations in IE2 also result in nonviable recombinant viruses, 
emphasizing the importance of IE2 in HCMV replication. GST pulldown assays 
demonstrate that mutagenesis of Tyrosine 544 in IE2 reduces IE2 interactions with 
TATA binding protein (TBP) when compared to the wildtype IE2 protein. Using ChIP 
assays, we demonstrate that wildtype IE2 is recruited to the UL54 promoter in transiently 
transfected cells. However, mutagenesis in the IE2 protein at Proline 535 and Tyrosine 
544 significantly decrease recruitment of IE2 to the UL54 promoter. Interestingly, these 
functional defects in mutated IE2 protein had no effect on RNA polymerase II 
recruitment, suggesting that IE2 may function in transcriptional regulation after 
formation of the transcriptional pre-initiation complex. In this dissertation, we have 
further characterized regions and functional properties of IE2 essential for UL54 
activation and HCMV replication. Our studies are significant in understanding the 
regulation of viral genes essential for replication of HCMV and in the development of 
novel HCMV therapies. 
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CHAPTER I 
INTRODUCTION 
The family Herpesviridae 
The Herpesviridae family is generally categorized into three subfamilies: 
Alphaherpesvirinae, Betaherpesvirinae, and Gammaherpesvirinae. All members of the 
Herpesviridae family possess the ability to establish persistent and latent infections. 
Alphaherpesviruses are neurotropic viruses, such as herpes simplex virus (HSV)-l, HSV-
2, and varicella-zoster virus, which are characterized by a relatively rapid replication 
cycle and broad host cell specificity (115). The betaherpesviruses, including human 
cytomegalovirus (HCMV), human herpesvirus (HHV)-6 and HHV-7, are characterized 
by a slow life cycle and species-restricted host range (115). Gammaherpesviruses, 
including Epstein-Barr virus and Kaposi's sarcoma herpesvirus, are distinguished by 
slow replication and infection of lymphoid cells (115). Members of the herpesviruses 
represent an opportunistic group of viruses which are significant human pathogens. 
Human Cytomegalovirus 
General Properties 
HCMV is the most well characterized member of the Betaherpesvirinae 
subfamily. It is distinguishable from other herpesvirus due to its high species-specificity 
and slow replication period and growth in cultured cells (64). HCMV is a ubiquitous and 
opportunistic pathogen, easily controlled by a functional immune system in immuno-
This dissertation follows the format of Journal of Virology. 
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competent individuals. In normal, immuno-competent populations, HCMV infections are 
usually asymptomatic, although infection may cause a brief mononucleosis-like condition 
in some individuals (64). However, in conditions of immune immaturity or suppression, 
such as neonates, transplant recipients, and AIDS patients, HCMV is a major cause of 
disease and mortality (64). Epithelial cells in the upper alimentary, respiratory and 
genito-urinary tracts are thought to be the primary sites of viral replication following 
direct contact (110). After infection, macrophage and endothelial-cell associated virus is 
important in the transmission of virus to other host tissues, such as the heart, lung, liver, 
and spleen. HCMV can replicate in several cell types including human fibroblasts, 
epithelial cells, endothelial cells, vascular smooth muscle and macrophages (126). 
Clinical Significance of HCMV 
In the United States, HCMV infection occurs at a rate of 1.6 infections per 100 
susceptible individuals between 12-49 years of age (25). This rate of infection increases 
significantly in non-Hispanic Black, Mexican American, and low income populations 
(25). The virus persists throughout an individual's lifetime, and can reactivate in 
immunosuppressed periods to cause viral disease. HCMV is transmitted through several 
mechanisms: (1) horizontally, through direct contact with bodily fluids such as urine, 
semen or saliva, (2) vertically, or in utero, from an infected mother to her unborn child 
and (3) through organ transplants or medical transfusions of blood, platelets, and white 
blood cells (67,104). 
Infections of most immuno-competent individuals are subclinical and adverse 
symptoms are limited. However, HCMV infection causes severe disease and mortality in 
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individuals with compromised immune systems such as patients with AIDS, patients 
being treated with chemotherapy and patients undergoing immuno-suppressive therapies 
for tissue and solid organ transplantation (33, 67, 94, 104). Significant clinical symptoms 
include retinitis, gastrointestinal infections, pneumonia and a strong association with 
organ rejection (31). Furthermore, HCMV is known to be the major viral cause of birth 
defects leading to mental retardation and hearing loss (36, 87, 104). Current treatments 
for HCMV include ganciclovir and foscarnet, which target the viral DNA polymerase 
(85). However, since 1991 a number of HCMV strains resistant to ganciclovir and 
foscarnet have been isolated from patients and well characterized, demonstrating 
diminished efficacy of these treatments (130). Thus, novel therapeutic strategies are 
needed to effectively treat HCMV infection. 
Virion Structure and Morphology 
The virion of HCMV consists of a double stranded, DNA genome (235 kb) 
contained within an icosahedral capsid, a tegument region surrounding the viral capsid, 
and a lipid bilayer envelope studded with various virus-encoded glycoproteins (Fig. 1) 
(94). The capsid is approximately 100-nm in diameter and mature virions range from 
150 and 200 nm (64). The HCMV capsid is composed of five structural proteins: the 
major capsid protein (MCP; pUL86), minor capsid protein (mCP; pUL85), minor capsid 
binding protein (mC-BP; pUL46), the smallest capsid protein (SCP; pUL48-49) and 
portions of the assembly protein (pUL80) (13, 38-40, 51, 123). A tegument or matrix 
region, is located between the capsid and the envelope (64). The tegument is composed 
of approximately 20 proteins with pp65 (ppUL83), pp28 (ppUL83), pp71 (ppUL82) and 
4 
Tegument 
Glycoproteins 
DNA genom 
Capsid 
Envelope 
FIG. 1. Schematic diagram of the HCMV virion structure. Mature HCMV virions 
contain a large double stranded, DNA genome surrounded by an icosahedral capsid. The 
entire virion is surrounded by a lipid bilayer studded with glycoproteins. Between the 
capsid and the lipid bilayer is a region called the tegument. 
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ppl50 (ppUL32) being the most abundant tegument proteins (6, 118). In addition, a 
more recent study by Varnum, et al. identified a number of cellular and viral proteins 
located in the HCMV virion through proteomic approaches (141). Approximately 59 
viral structural proteins and over 70 host cellular proteins, including enzymes and 
chaperone proteins, have been identified suggesting a possible role of these proteins in 
the initiation of viral infection (141). 
Genome Organization 
The 235-kb double-stranded, linear DNA genome of HCMV is separated into 2 
covalently linked segments, referred to as the unique long (UL) and unique short (US) 
region (Fig. 2) (19). Each segment is flanked by internal (IRL, IRS) and terminal repeat 
(TRL, TRS) sequences. Gene loci are identified according to their position in the 
genome (TRL, UL, IRL, IRS, US, and TRL) (94). 
Lytic (Productive) Infection. 
HCMV replicates in a number of susceptible cell types, including epithelial cells, 
endothelial cells, macrophages, smooth muscle tissues and fibroblasts (Fig. 3) (94). Viral 
entry involves attachment of virus to the cell surface through glycoprotein gM and gN 
interactions with heparin sulphate proteoglycan complexes on the cell surface (94). The 
viral glycoprotein, gB, has also been found to interact with the epithelial growth factor 
receptor (EGFR) to initiate viral entry (145). However, several EGFR-negative cell lines 
are permissive to HCMV infection, suggesting other receptors are involved in 
attachment/penetration of the virion (52). Following attachment of the 
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FIG. 2. Genomic Organization of HCMV. The HCMV genome contains two unique 
segments, unique long and unique short (solid lines), flanked by inverted repeat 
sequences (open rectangles). Gene loci are named according to their position along the 
genome. 
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1 Viral Attachment 
2 Viral Fusion/Entry 
3 Transit to the Nucleus 
4 Circularization of Viral DNA 
5 Viral Gene Expression 
Capsid Assembly 
7 Exiting 
8 Capsid Maturation 
9 Budding of Capsid from 
Golgi 
10 Virus Budding 
FIG. 3. The HCMV replication cycle. Please refer to text for additional information on 
HCMV replication. 
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viral particle to the cell surface, fusion occurs between the cell membrane and the viral 
envelope. The gH/gL/gO heterotrimeric complex is required for membrane fusion (49). 
The virus particle is then released into the cytoplasm and within minutes, transits to the 
nucleus. Transport through the nuclear pore allows the viral DNA to be deposited into 
the nucleus and to be transcribed into mRNA by the cellular DNA dependent RNA 
polymerase II (31). 
A number of cellular signaling pathways are activated by binding and/or fusion of 
the HCMV virion to the cell membranes (32). Several pathways thought to be important 
for successful virus replication and immune evasion are activated, including modulation 
of calcium levels, activation of phospholipases C and A2, and release of arachidonic acid 
and subsequent metabolites (32). Activation of these pathways occur in the absence of 
viral expression, as demonstrated through the use of UV-inactivated virus, suggesting 
these actions are triggered by structural proteins involved in viral attachment and/or 
penetration. Viral attachment also triggers activation of cellular factors such as SP1, 
myc, c-fos/c-jun, NF-KB, ERK1/2, p38, and phosphatidylinositol 3-kinase (PI3-kinase) 
which are thought to prepare the cell for virus infection (8, 10, 56, 66, 157). In addition, 
prior to de novo protein synthesis, attachment and penetration of HCMV is able to trigger 
immediate effects on the host cell through the actions of tegument proteins and 
glycoproteins (33). Specifically, pp71, a tegument protein, has been shown to enhance 
activation of cellular promoters containing CREB/ATF and AP-1 regulatory elements 
(75). 
Similar to other herpesvirus, the expression of HCMV genes are temporally 
regulated within the nucleus of the host cell in the following order: immediate early (IE), 
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early and late gene expression (64). The first subset of viral genes to be expressed are the 
IE gene products (64). The major IE (MIE) proteins, including IE1 and IE2, are the most 
abundantly expressed proteins during the IE phase (16, 94). Unlike early and late genes, 
IE genes do not require de novo cellular or viral protein synthesis, as determined by 
cyclohexamide treatment, and can be expressed within several hours following infection 
(64). As mentioned previously, IE promoters are primarily dependent on cellular proteins 
already present in the cell for activation (32). 
A large majority of IE proteins facilitate the activation of HCMV early genes 
(104, 148). Early genes are typically involved in the replication of the viral genome and 
may code for structural proteins (94). Examples of early viral genes required for 
replication include the UL54 gene, which encodes the virus DNA polymerase, and 
UL112-113 gene products, which encode a number of phosphoproteins required for 
replication (94). 
Late gene products are produced after initiation of DNA replication and encode 
proteins primarily involved in virion assembly, maturation, and spread (94). In addition 
to early gene activation, several of the IE proteins are involved in activation of late genes. 
For example, IE2 regulates expression of pp28, a tegument protein (60). 
HCMV DNA replication begins approximately 24 hours post-infection (hpi) and 
peaks at 48-72 hours in human fibroblasts (88). Viral DNA replication occurs through a 
rolling circle mechanism resulting in concatemeric molecules (88). DNA is then cleaved 
and packaged into capsids as linear, double stranded DNA (88). After packaging, current 
research suggests that HCMV intranuclear capsids bud through the nuclear membrane, 
losing their primary envelope, and acquire a final envelope and tegument in cytoplasmic 
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compartments (93). Following tegumentation, the viral particle undergoes a second 
envelopment in the trans-golgi. assembly compartment where it will obtain additional 
viral glycoproteins (13, 93). Finally, HCMV particles are released from the cell and enter 
into the intercellular space in order to infect nearby cells (93). 
HCMV Transcriptional Regulation 
Transcriptional regulation of cellular and viral genes is a highly controlled and 
regulated process (Fig. 4). During virus infection, HCMV "hijacks" the cellular 
transcription machinery to enable transcription of viral genes (32). Transcription of 
cellular genes involves the assembly of a transcription pre-initiation complex at the 
transcription start site (+1) of the designated promoter (15). The TATA box, located at 
position -25 to -30, is recognized by the TATA-binding protein (TBP), a component of 
the TFIID complex. The TFIID complex consists of TBP and TBP-associated factors 
(TAFs). TFIIA and TFIIB are then recruited to the pre-initiation complex to assist in 
TFIID binding. Next, TFIIF and RNA polymerase II bind to the pre-initiation complex. 
TFIIE and TFIIH are recruited to allow transcriptional initiation and RNA polymerase II 
phosphorylation (15). 
General transcription factors, such as SP1, CREB, and/or API aid in recruitment 
of the TBP and RNA polymerase II protein complex to the promoter (47, 73). 
Transcription factors also facilitate recruitment of two types of enzymes, ATP-dependent 
chromatin remodeling enzymes and histone-modifying enzymes which function to 
control accessibility of the transcriptional machinery to the promoter (96, 139, 140). 
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FIG. 4. Assembly of the Basal Transcription Machinery in Eukaryotic Cells. Initiation 
of transcription in eukaryotic cells involves a complex interplay of cellular factors 
recruited to individual promoters. Please refer to the text for additional information on 
transcriptional initiation. 
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ATP-dependent chromatin remodelers, such as SWI/SNF and Gcn5, disrupt histone-DNA 
contacts of the nucleosome (96, 139, 140). Histone modifying enzymes, such as P/CAF 
or p300/CBP, posttranscriptionally modify the N- and C-terminal tails of histone proteins 
for transcriptional regulation (7, 96, 139, 140). 
Most regulatory proteins involved in eukaryotic gene transcription are termed 
activator or repressor proteins and possess a modular structure comprised of distinct 
functional domains including, but not limited to, a DNA binding and a transcriptional 
regulatory domain (11, 34). The DNA binding domain is usually specific for individual 
promoter sequences (34). The transcriptional regulatory domain facilitates transcriptional 
activation or repression through properties such as recruitment of co-regulators or 
interactions with basal transcription machinery (23, 24, 34). 
Coactivators are proteins that do not bind directly to DNA, but function in 
transcriptional activation of RNA polymerase II promoters. Coactivators can regulate 
transcription by one or more of the following mechanisms (1) serving as a scaffolding 
factor at the promoter between transcription factors and members of the basal 
transcription machinery, (2) interacting with the basal transcription machinery, and/or (3) 
recruiting or functioning as histone modifiers (42, 55, 95, 100, 101, 150). 
HCMV infection leads to an increase in the RNA and DNA synthesis within an 
infected cell, including an increase in expression of cellular transcription factors (32, 
129). The IE2 protein is then able to interact with several cellular proteins involved in 
transcriptional regulation. IE2 has been shown to interact with members of the basal 
transcription machinery, including TBP, TFIID, and TBP-associated factors (TAFs) (43, 
44, 57, 58). IE2 also interacts with a number of cellular transcription factors such as SP1, 
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API, and CREB (68, 119, 120, 146). In addition, IE2 has been found to interact with 
chromatin remodeling proteins such as P/CAF, p300/CBP, and HDAC3 (14, 98). Based 
on these properties of transcriptional regulation, IE2 appears to function as a coactivator 
to stimulate activation of several viral promoters. In this dissertation, we will further 
investigate the functions of IE2 at viral promoters and identify properties involved in 
regulation of transcription. 
Properties of the IE2 Protein 
IE2 Gene Expression 
The majority of IE transcription occurs from the UL122/123 gene region, termed 
the major IE gene region (Fig. 5) (19). The major IE gene region encodes several splice 
variants during virus infection (135, 136, 138). The IE1 72 kDa and IE2 86 kDa proteins 
are the most abundantly expressed gene products from this locus and play a significant 
role in transcriptional regulation of viral genes (16, 94). These gene products share 85 
amino acids in the N-terminus (135, 136, 138). In addition, the MIE promoter drives 
expression of a number of minor transcripts with sequences overlapping IE1 and IE2 
which are currently not well-characterized (54, 63, 111, 125, 133). Regulation of the 
MIE promoter is controlled by both cellular and viral factors, as described later in this 
dissertation. 
Regulation of Viral Gene Transcription 
IE2 is a potent transactivator of viral and cellular genes and is essential for viral 
replication (45, 74, 86,107,109,134). This protein activates a number of HCMV early 
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FIG. 5. Genomic Organization of the MIE Gene Region (UL122-123). The major IE 
gene region (UL122-123) is the most extensively transcribed region during the immediate 
early phase of viral gene expression. The major IE promoter encodes a number of splice 
variants (not all variants are shown). The IE1 and IE2 gene products are the most 
predominant UL 122-123 gene products expressed. Figure adapted from (79). 
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promoters that are required for viral replication, including the UL112/113 (encoding four 
phosphoproteins required for replication) and UL54 (encoding the viral DNA 
polymerase) gene promoters. IE2 also activates a variety of heterologous cellular and 
viral promoters, regulating expression of the cyclin E, c-fos, hsp70 genes and the human 
immunodeficiency type I (HIV-1) long terminal repeat (28, 94, 120, 121, 128, 132, 156). 
Regulation of viral and cellular genes is thought to be mediated by direct binding 
of IE2 to DNA and/or protein interactions with cellular and viral transcription factors (33, 
128). Activation of TATA-containing promoters, such as the c-fos and HIV LTR 
promoter, is thought to be mediated by IE2 interactions with members of the basal 
transcription machinery, TFIIB and TBP (43, 44, 57, 58). IE2 is also able to interact with 
cellular transcription factors to regulate viral gene transactivation, including SP1, CREB, 
API (68, 119, 120, 146). In addition, IE2 has been found to interact with histone 
modifiers such as P/CAF and HDAC3, suggesting IE2 is involved in chromatin 
modification to facilitate transcriptional activation (15, 95, 155). IE2 can also regulate 
early gene transcription by direct binding to DNA (2, 18, 48, 121, 122). For example, 
expression of UL112-113 gene products is regulated by an ATF/CREB binding site and a 
nonessential IE2 binding site, identified by deletion mutagenesis and gel mobility shift 
analysis (120, 121). Deletion of this IE2 binding site in UL112-113 within a HCMV 
recombinant virus causes a reduction of IE2-mediated transactivation of this promoter 
during infection (114). 
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Structure-Function Analysis 
As a result of the essential role of IE2 in viral replication, numerous studies have 
been performed to identify functional domains of the IE2 protein and assess the 
biological significance of these regions (Fig. 6). Two distinct regions of the N- and C-
terminus of IE2 are involved in transactivation of early genes (amino acids 1-98 and 195-
570) (46, 84, 108, 122, 127, 134, 154). In addition to a transactivation function, the C-
terminus of IE2 also plays a role in autoregulation (20, 48, 69, 74, 83, 107) and binding 
to cellular transcription factors and members of the basal transcription machinery (17, 22, 
58, 127). Due to this large overlap of function domains, it is difficult to determine 
specific regions of IE2 important for a single function. Mutational analyses of IE2 
performed by Asmar, et al. identified a region in IE2 between amino acids 450 and 544 
that plays a major role in IE2 transcriptional regulatory properties during transient 
transfections, referred to as the "core" region (3). Mutations in the core region of 
transfected fibroblasts disrupted DNA binding of IE2 to the MIE promoter, 
autoregulation of the MIE promoter and transactivation of UL112-113 promoter (3). 
Research in our laboratory has shown that insertion of 4 amino acids at amino acid 349 or 
540 result in a 6-fold or greater decrease in activation of the UL54 promoter in transient 
transfections (134). These insertions also resulted in a 10-fold increase of MIEP 
activation (134). Based on these results, it has been suggested that the IE2 regions 
involved in transcriptional activation and repression overlap. However, these large scale 
mutations in IE2 most likely disrupt one or more functional properties of IE2, 
emphasizing the need to examine these properties using single amino acid mutations. 
More recent studies involving less intrusive mutagenesis of IE2 have confirmed 
17 
(Amino Acids 535 to 545) 
IE2 FUNCTION 
ACTIVATION 
AUTOREGULATION 
Zn FINGER 
TFIIB INTERACTION 
TBP INTERACTION 
Rb INTERACTION 
P53 INTERACTION 
DIMERIZATION 
DNA BINDING 
1 
r R ...'. • • > • * > ' , I
5 7 9 
| Core Region 
1 
J
98 
85 
45 
195 
""135 
290 
290 
A26~A52 
3$b"" 
370 390 
390 
390 
388 
376 
fe04 
| 
57 
57J 
542 
579 
579 
547 
FIG. 6. Structure-Function Analysis of the IE2 Protein. Mutational analyses of the IE2 
genes in transient transfection assays have identified a number of functional domains in 
IE2 gene region. This dissertation focuses on the region between amino acids 535 and 
545 of IE2. This region overlaps several functional domains of IE2 including sequences 
involved in transactivation (46, 84, 108, 122, 127, 134, 154), interactions with cellular 
transcription factors (17, 22, 58, 127), dimerization (82, 83) and DNA binding (20, 48, 
69, 74, 83, 107). The IE2 gene contains the following structural domains: a nuclear 
localization sequence, a leucine rich region, and a putative zinc finger domain (35, 84, 
108,134). 
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the importance of the "core" region in IE2 function in transient transfections and during 
virus infection. Petrik et al. demonstrated that a double mutation in IE2 at amino acid 
535 and 537 prevented early gene activation of UL44, UL54 and IRL7 promoters in the 
context of the viral genome (105). IE2 protein mutated at amino acid 535/537 was still 
able to bind and autoregulate the MIE promoter, suggesting the domains involved in IE 
autorepression and early gene activation are distinct (105). IE2 protein mutated at amino 
acid 535/537 was also unable to bind to the UL4 and UL112 promoters. In 2004, White 
et al. generated internal amino acid mutations or deletions in IE2 between amino acids 
356 to 359, 427 to 435, and 505 to 511 within HCMV bacterial artificial chromosomes 
(BAC) (149). These mutations inhibited expression of the UL44 and UL112-113 early 
genes during infection (149). In addition, these mutations did not result in viable virus 
(149). However, White et al. did not address functional properties of IE2 which may 
have been impaired with mutations in IE2 (105). In addition, in both of the 
aforementioned studies the authors did not look directly at the effects of single amino 
acid mutations on transcriptional regulation. Thus, it is possible that more than one 
functional property of IE2 was disrupted. The experiments presented in the dissertation 
will examine transcriptional regulation of IE and early viral promoters by IE2 protein 
mutated in single amino acids and identify IE2 functional properties disrupted by these 
mutations. 
Regulation of the MIE Promoter 
The major IE promoter (MIEP) is regulated by a complex interplay between viral 
and cellular proteins. Prior to synthesis of viral gene products, the MIEP is primarily 
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regulated by cellular transcription factors, such as NF-KB, CREB, SP1, ERF, and YY1. 
The IE1 and pp71 viral proteins increase activation of the MIE promoter leading to 
increased MIE gene products (4, 12, 21, 75, 84, 134, 137). 
In contrast, IE2 negatively regulates expression of the MIE gene products (20, 48, 
69, 74, 83, 107). Negative regulation is typically required to prevent overexpression of 
viral genes and subsequent inhibition of virus replication. Since IE2 regulates a variety 
of cellular and viral promoters, including genes involved in cell cycle regulation, 
uncontrolled expression of IE2 could be problematic to virus replication. IE2 is able to 
repress its own expression through direct binding to the cis repression sequence (CRS), 
located between the TATA box and the transcription start signal of the MIEP (31, 64, 70, 
109,144). This interaction has been confirmed by Xu, et al. using ChIP assays in HCMV 
infected cells (153). It is thought that IE2 inhibits transcription from the MIEP by 
blocking RNA polymerase recruitment and preventing assembly of the transcription 
initiation complex (72). Additional studies have demonstrated that transcription of the 
MIE gene products are also controlled by a number of cellular transcription factors (37, 
48, 76, 90, 99, 124, 151), The presence of proteins such as CREB/ATF, SP1, API, and 
NF-KB at the promoter function to enhance transcription of the MIE gene products (35, 
116, 142). A number of cellular factors also repress transcription of MIE gene products, 
such as MBF2, YY1, MRF, and ERF (37,48, 76, 90, 99, 124, 151). 
Regulation of Early Viral Promoters 
The UL54 early gene promoter encodes the viral DNA polymerase and is required 
for virus replication (102). This promoter is a well-characterized, prototypical early 
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promoter which is regulated by actions of both viral and cellular transcription factors (59, 
61, 62, 65, 81). Recent studies suggest, but have not directly shown, that IE2 functions 
in cooperation with cellular factors, TBP, ATF-1 and SP1, and viral factors, such as the 
UL112-113 gene products, to facilitate transactivation of UL54 promoter (17, 43, 57, 59, 
61,62,80). 
During HCMV infection, SP1 activity is significantly upregulated within the cell 
(80, 158). The SP1 protein recognizes specific GC-rich elements in viral promoters to 
allow direct DNA binding and to assist in transcriptional activation (29, 30). A SP1 
protein binding site on UL54 was mapped to an inverted repeat domain within the 
promoter using transient assays (59, 62). Generation of recombinant viruses containing 
mutations in the putative SP1 binding site of UL54 located upstream of a CAT gene 
demonstrated a delay in UL54 activation at early times in infection, suggesting a role of 
SP1 inUL54 expression (59, 62). 
Studies have revealed that the C-terminus of Spl is able to interact directly with 
the IE2 protein at viral gene promoters in transient assays (80, 158). In addition, several 
reports demonstrate that IE2 can interact with SP1 and increase transactivation of viral 
promoters using in vitro binding assays and reporter gene assays (59, 62, 81). IE2 has 
also been shown to interact with TBP (43, 152) and plays an important role in stabilizing 
the binding of TBP to the TATA box (57, 58). These studies suggest that IE2 may 
function as a scaffolding protein at the UL54 promoter in a complex with TBP and SP1. 
Viral transcription factors have also been implicated in the regulation of the UL54 
promoter. Expression of the IE1 gene product enhances UL54 activation in the presence 
of IE2 during transient assays (59). In addition to the MIE gene products, the UL112-113 
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locus encodes four phosphoproteins early in infection which serve of transactivators of 
the UL54 promoter (53). Studies show that the UL112-113 promoter is controlled by an 
essential ATF/CREB and a nonessential IE2 binding site (113). 
Summary 
Previous studies in our laboratory identified a region in the C-terminus of IE2 
important in transcriptional regulation of HCMV promoters (134). In addition, other 
laboratories have investigated regions within IE2 in order to identify regions of the 
protein essential for virus replication and transcriptional regulation (3, 105, 149). 
However, these studies did not assess functional defects of IE2 transcriptional regulatory 
properties and/or utilized IE2 protein containing multiple mutations. The work presented 
in this study uses both transient transfections and assessment in the context of the viral 
genome in order to more precisely define regions and functional properties of IE2 
required for transcriptional regulation of viral early promoters and replication. 
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CHAPTER II 
OBJECTIVES OF THIS WORK 
The objective of this study is to investigate the role of IE2 on transcriptional 
regulation of HCMV early promoters. Expression of the MIE, UL54, and UL112-113 
genes are required for successful virus infection. Previous research on transactivation of 
the early promoters has primarily been performed in transient assays. This project will 
assess viral gene regulation in both transient assays and in the context of the HCMV 
genome in order to further characterize the function of viral and cellular factors in early 
gene transactivation. These results will be significant in understanding the regulation of 
early viral genes essential for replication and successful virus infection. The specific aims 
of this study were to: 
Specific Aims 
1. Identify the regions of IE2 required for transcriptional regulation of viral 
promoters in transient assays. 
Transcriptional activation of the early viral genes, such as UL54 and UL112-
113, is essential for HCMV replication in the cell. IE2 is a key transcriptional 
regulator of the early viral genes during virus infection. IE2 is able to autoregulate its 
own expression by repression of the major IE (MIE) promoter. Previous studies have 
also identified regions of IE2 important in transcriptional regulation at the C-terminus 
of IE2. Site-directed mutagenesis was used to generate single amino acid mutations 
within this region of the IE2 protein at amino acids 535 to 545. Luciferase reporter 
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assays were performed to assess the ability of IE2 to activate early gene promoters 
and repress the MIE promoter. These assays were performed in the presence or 
absence of other MIE gene products to assess IE2-specific properties. Real time PCR 
and western blot analysis were used to assess differences in IE2 RNA and protein 
expression levels, respectively. 
Characterize the effects of mutations in IE2 on replication and transcription 
regulation of viral promoters during HCMV infection. 
Due to the essential nature of the IE2 protein for virus replication, it is 
difficult to generate recombinant virus through traditional methods. To assess the 
effects of mutations in the IE2 C-terminus on virus replication, we generated HCMV 
recombinant bacterial artificial chromosomes (BACs) containing mutations in the IE2 
protein using homologous recombination. Recombinant HCMV BACs were 
transfected into human fibroblasts and monitored for cytotoxity and plaque formation 
to assess the ability to form infectious virus. Virus replication and DNA replication 
assays were performed to ensure manipulation of the original BAC construct did not 
influence virus replication using parental and wildtype revertant virus. To determine 
the effects of mutations in IE2 on transcriptional regulation of viral promoters, RNA 
was harvested from BAC-transfected fibroblasts at various times post transfection and 
assessed for viral gene expression by real time RT-PCR analysis. 
Characterize the effects of mutation in IE2 on functional properties of IE2 
important in UL54 activation. 
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IE2 regulates transcription of viral genes through several potential 
mechanisms. In order to characterize functional properties of IE2 required for UL54 
activation, we used in vitro GST pulldown assays to assess the ability of mutated IE2 
protein to interact with TBP, a member of the basal transcription machinery. 
Chromatin immunoprecipitations (ChIP) were performed to investigate recruitment of 
the IE2 protein and RNA polymerase II to the UL54 promoter during transient 
transfections. 
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CHAPTER III 
MUTATIONS IN IE2 DISRUPT TRANSCRIPTIONAL REGULATION OF VIRAL 
PROMOTERS IN TRANSIENT TRANSFECTIONS 
Introduction 
IE2 is a potent transcriptional regulator of viral and cellular genes and is essential 
for viral replication (45, 74, 86, 107, 109, 134). This protein regulates a number of 
HCMV promoters encoding proteins required for virus replication, including the MIE, 
UL112/113 and UL54 promoters. Regulation of viral and cellular genes is thought to be 
mediated by direct binding of IE2 to DNA and/or protein interactions of IE2 with cellular 
factors, such as members of the basal transcription machinery, TFIIB and TBP (43, 44, 
57, 58). IE2 is also able to interact with cellular transcription factors to regulate viral 
gene transactivation, including SP1, CREB, API (68, 119, 120, 146). In addition, IE2 
has been found to interact with histone modifiers such as P/CAF and HDAC3, suggesting 
IE2 is involved in chromatin modification to facilitate transcriptional activation (14, 98, 
159). 
IE2 can also regulate early gene transcription by direct binding to DNA (2, 18, 48, 
121, 122). IE2 is able to repress its own expression through direct binding to the CRS, 
located between the TATA box and the transcription start signal of the MIEP (31, 64, 70, 
109, 144). It is thought that IE2 inhibits transcription from the MIEP by blocking RNA 
polymerase II recruitment and preventing assembly of the transcription initiation complex 
(72). 
The purpose of the experiments outlined in this chapter was to investigate regions 
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of the IE2 protein essential for transcriptional regulation of viral promoters. The C-
terminus of IE2 has been previously investigated by mutational analysis; however, few 
studies have used single amino acid mutagenesis to begin narrowing down specific 
functions involved in the regulation of individual promoters (3, 5, 105, 149). Therefore, 
we sought to investigate the effects of single amino acid mutations in IE2 on 
transcriptional regulation of the viral gene promoters by the following two approaches. 
First, to determine the effects of mutations in IE2 on transcriptional regulation of 
essential genes, we generated single amino acid mutations in IE2 at a region surrounding 
amino acid 540 and evaluated the effects of the mutated constructs on the MIE, UL54 and 
UL112-113 early gene regulation. This region was chosen due to it conserved sequence 
homology with CMV from other species (Fig. 7) and previous studies in our laboratory 
demonstrating that insertion of a four amino acid linker sequence at amino acid 540 
resulted in decreased UL54 activation in transient transfections (105, 134). This 
approach allowed us to identify specific amino acid mutations which disrupted 
transcriptional regulation of essential early genes. Second, we investigated the effects of 
specific amino acid mutations on IE2 RNA and protein expression. Since the MIE 
promoter is auto-regulated by IE2 it is possible that mutations which inhibit 
transactivation of early genes may also interfere with IE2-mediated repression of the MIE 
promoter. This approach allowed us to determine if mutations in IE2 affect expression of 
the MIE gene products during transient transfections. These experiments will be 
significant in the identification of regions within IE2 important for transcriptional 
regulation of early and/or IE genes. 
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Human 528 NQGGfMLIIYETATKAYftVGQFEQP 
Chimp 548 NQSSEMLPIXESMKftYAVGQFEEP 
Rat 473 VGGLQPLPIXEKVVmriyrQYNFS 
Mouse 571 TGGLNPLPHEETVSSYVKaQFEflD 
Rhesus 572 NSNSM,PIYDQAftKMYAVCQFEET 
Amino Acids 535 to 545 
FIG. 7. Sequence similarity between CMV species. The HCMV IE2 protein shares 
sequence similarity at amino acids 535 to 545 in the C-terminus (shaded area) with a 
number of other CMV species suggesting this region may be important in virus 
infections. This figure was adapted from (105). 
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Materials and Methods 
Mammalian Cells 
Primary human foreskin fibroblasts (HFF) were obtained from Clonetics 
Corporation and grown in Dulbecco's Modified Eagle's Medium (DMEM; Invitrogen) 
with 10% Newborn Calf Serum (Invitrogen), 2 mM L-glutamine, 100 IU/mL penicillin 
and 100 [ig/mL streptomycin (Sigma). Cells were split at a ratio of 1:2 once a week. 
Plasmids Used for Evaluation of Transcriptional Regulation 
IE2 Plasmids 
For transient expression of IE2 and other MIE gene products in culture, the 
pSVHk plasmid was generated by deletion of a Kpnl restriction enzyme site in the pSVH 
plasmid (27). This plasmid contains the entire UL122-123 coding sequence under the 
control of the native MIE promoter. pMCRS86 was received as a gift from Jay Nelson 
(Oregon Health and Science University). pMCRS86 contains the IE2 cDNA sequence 
under the control of a mutated MIE promoter, allowing for transient expression of the IE2 
protein alone. The promoter contains a mutation within the cis repression sequence 
(CRS) mutated between nucleotide -2 and -12 to prevent auto-regulation by IE2. For 
correction of aberrant mutations in IE2 within the original pMCRS86 construct, the 
SmaI-Bsu36I fragment from pSVHk was extracted and transferred into pMCRS86 (as 
described in (5)). 
Mutagenesis of IE2 in the pSVHk and pMCRS86 constructs was achieved using 
Stratagene's Site-directed PCR mutagenesis kit XL according to the manufacturer's 
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instructions and using a PCR extension time of 7 minutes. Primer sequences for 
individual mutations are shown in TABLE 1. 
The pS VOd plasmid was used as an empty control vector and has been previously 
described (91). 
Luciferase Reporter Plasmids 
For luciferase reporter assays, the promoter regions of the MIE, UL54 and 
UL112-113 promoter were cloned upstream of a luciferase reporter gene to generate 
pMIEP-Luc, pPol-Luc and pULl 12-113-Luc, respectively. pMIEP-Luc and pUL54-Luc 
were generated by cloning of a Hindlll fragment from pCAT760, kindly provided by 
Mark Stinski (137), and pPolCAT (134) into pGL3-Basic (Promega), respectively. 
pULl 12-113-Luc was generated by PCR amplication of p729CAT, kindly provided by 
Deborah Spector (University of California, San Diego, CA), and TA cloning into pCR4-
TOPO (Invitrogen) according to the manufacturer's instructions. The UL112-113 
promoter was cloned into pGL3-Basic (Promega) following Hindlll and Bglll digestion 
(131). 
Real Time PCR Plasmids 
IE2 and glyceraldehyde 6-phosphate dehydrogenase (G6PD) plasmids were 
generated by PCR amplification of cDNA from HCMV-infected transfected primary 
fibroblasts using IE2 and G6PD primers described in White et al. to generate IE2-TOPO 
and G6PD-TOPO (149). PCR fragments were TA cloned into pCR4-TOPO according to 
the manufacturer's instructions. 
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TABLE 1. Primers used for site-directed PCR mutagenesis. 
Primer Primer Sequence a,b Mutation 
P535A-2 5' GTGGGTTCATGCTGGCTATCTACGAGACGGC 3' Pro 535->Ala 
I536A 5' GGTTCATGCTGCCTGCCTACGAGACGGCCA 3' He 536->Ala 
Y537A 5' CATGCTGCCTATCGCCGAGACGGCCACG 3' Try 537->Ala 
E538A 5' GTTCATGCTGCCTATCTACGCGACGGCCACGAAGG 3' Asn 538->Ala 
T539A 5'CCTATCTACGAGGCGGCCACGAAGGC 3' Try 539->Ala 
A540V 5' TATCTACGAGACGGTCACGAAGGCCTACGC 3' Ala 540->Val 
T541A 5'CTATCTACGAGACGGCCGCGAAGGCCTA 3' Try541->Ala 
K542A 5' TATCTACGAGACGGCCACGGCGGCCTACGC 3' Asn 542->Ala 
A543V 5' GGCCACGAAGGJCTACGCCGTGGG 3' Ala 543->Val 
Y544A 5'CCACGAAGGCCGCCGCCGTGGGGC 3' Try544->Ala 
A545V 5' CGAAGGCCTACGTCGTGGGGCAGTTTGA 3' Ala 545->Ala 
" All primers were phosphorylated on the 5' end. 
6
 Only forward primer sequence shown for each primer set and mutations in IE2 are underlined. 
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Molecular Cloning and Generation of Plasmid DNA 
Restriction Enzyme Digestion of Plasmid DNA. 
For cloning of plasmid DNA, restriction enzyme digestions were performed 
according to the manufacturers' recommendation (New England Biolabs). For 
confirmation of restriction enzyme digestion patterns, approximately 500 ng of DNA was 
digested for 2-3 hours with 1.5-3 units of enzyme in a total reaction volume of 10-15 ul. 
Following confirmation of digestion patterns on a 1.2% agarose gel, approximately 10 ug 
of plasmid DNA was digested with 30-50 units of enzyme for 4-5 hours. Following 
electrophoresis, agarose gels were stained in 10 mg/ml of ethidium bromide and imaged 
using Kodak Gel Logic 200 Imaging System. 
Isolation of DNA fragments for cloning 
For cloning of plasmid DNA, the restriction enzyme reactions described above 
were separated by gel electrophoresis on a 0.8% low melt agarose gel. Following 
electrophoresis, agarose gels were stained in 10 mg/ml of ethidium bromide. The 
fragment of interest was excised from the gel and processed with a QIAquik DNA 
extraction kit (Qiagen) according to the manufacturer's instructions. 
Ligation of DNA fragments for Cloning 
For ligation of DNA fragments to generate new plasmids, ligation reactions were 
performed at molar ratio of 1:3 between insert and vector fragments according to the 
manufacturer's instructions of the T4 DNA ligase (Invitrogen). Briefly, approximately 
100 ng of vector DNA was combined with 3-fold molar amount of insert DNA, 1 unit of 
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T4 DNA ligase, and IX T4 DNA ligation buffer. The reaction was incubated overnight 
at 4°C. Following incubation, 1-5 ul of the reaction mix was used for transformation 
into chemi-competent XL1 blue cells. 
Generation of Chemi-competent XL1 Blue cells for Transformation and Propagation of 
PlasmidDNA 
For preparation of chemically competent XL 1-Blue cells for transformation of 
plasmid DNA, an overnight culture of XL-1 cells was inoculated from a single colony 
into 5 mis of Luria broth (LB) media and grown overnight at 37°C. Two hundred and 
fifty milliliters of LB was then inoculated with 3 mis of the overnight culture and grown 
at 37°C with shaking until OD550 of 0.4-0.5. Cells were chilled by swirling in an ice-
water bath 1-2 minutes then centrifuged at 5000 X g for 10 minutes at 4°C. The 
supernatant was then removed and the pellet was gently re-suspended in 100 ml cold 100 
raM CaCL;. Cells were then chilled on ice for 30 minutes, with swirling every 5 to 10 
minutes. Following centrifugation at 5000 X g for 10 minutes at 4°C, the cells were then 
re-suspended in 8 ml Calcium/Glycerol. Cells were separated into 250 ul aliquots, frozen 
in a dry-ice ethanol bath, and stored at -80°C. 
Transformation of Plasmid DNA 
For transformation and amplification of plasmid DNA, chemi-competent XL1 
blue cells were thawed on ice for 10-20 minutes. After cells had thawed, 100 ul of 
competent cells to was added to 10-100 ng of DNA to be transformed in a pre-chilled 
eppendorf tube. Cells plus DNA were incubated on ice for 30 minutes followed by a heat 
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shock at 42°C for 2.5 minutes. To allow cells to recover after the heat shock, 1 ml of LB 
of was added to the cells plus DNA and incubated at 37°C for 60-90 minutes with 
shaking. Following recovery at 37°C, 50-200 ul of cells were plated onto LB-agar 
containing appropriate antibiotic and incubated at 37°C overnight. 
DNA Isolation and Purification from Bacterial Cells 
For amplification of plasmid DNA, a single colony was used to inoculate a 5 ml 
culture of LB with the appropriate antibiotic. The following day, 4 mis of the culture was 
centrifuged at 5,000 X g for 5 minutes and the supernatant was removed. Small scale 
DNA purifications were performed using Qiagen's MiniPrep kit following the 
manufacturer's instructions. Following confirmation of small scale cultures by PCR 
analysis and restriction enzyme analysis as previously described, 0.5 ml of the residual 5 
ml culture was diluted 1:500 and grown overnight in 250 mis of LB with the appropriate 
antibiotic. The 250 ml culture was centrifuged at 6,000 X g for 15 minutes and the 
supernatant was removed. Large scale DNA purifications were performed using 
Qiagen's MaxiPrep kit according to the manufacturer's instructions. 
Sequencing of Plasmid DNA 
To confirm that manipulations of plasmid DNA did not alter the nucleotide 
sequence and/or generated the designed mutations, sequencing reactions were performed 
using BigDye Terminator v3.1 Cycle Sequencing kit according to the manufacturer's 
instructions with the following exception: the BigDye Ready Reaction mix was diluted 
1:8 for each reaction. Sequencing was performed by an ABI Primer 3130 Genetic 
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Analyzer. Sequencing of the IE2 gene was confirmed with the following primers: 
SeqPrimerl (5' AAT TGC ACA CCC ACC AAT TA 3'), SeqPrimer 2 (5' AAG AAG 
AAG AGC AAA CGC ATC 3'), SeqPrimer 3 (5' GAT TAT TAA ACC GCC CGT G 3'), 
SeqPrimer4 (5' CGA CGT TCC TGC AGA CTA TG 3'), SeqPrimer5R (5' CCT CGG 
TCA CTC GTT CAA AAG 3'). These primers bind at codons corresponding to amino 
acids 501, 335, 194, 60, and 72, respectively. 
Transfection of Human Foreskin Fibroblasts with Plasmid DNA 
Primary fibroblast cells were transfected with plasmids at 80% confluency by the 
DEAE-dextran technique (103). Twenty-four hours prior to transfection, cells were 
seeded at 0.25 million cells/well or 1 million cells/plate for a 6-well plate or 100 mm 
plate, respectively. Briefly, 2.5 or 10 ug of total DNA was used for each well in a 6-well 
plate or 100 mm plate, respectively. An equal amount of pEGFP-C3 (BD Biosciences 
Clontech) which results in expression of a green fluorescent protein (GFP) was 
transfected into a separate well of fibroblasts as a control for transfection efficiency. 
Cells were incubated in 1ml of IX TBS (30 mM Tris, pH 7.5, 150 mM NaCl) and 0.5 mg 
DEAE-dextran (diluted in 50 ul of IX TBS) for 30 minutes. Following incubation at 
37°C, 10 mM Chloroquine was added to cells for 2.5 hours. Cells were washed in IX 
TBS and new media was added. The cells were harvested 48 hours after the media was 
changed. 
Analysis of Early Gene Activation using Luciferase Assays 
Luciferase reporters and expression plasmids were transfected into human 
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fibroblasts using DEAE dextran transfection methods as previously described. Cell 
extracts were harvested using Cell Culture Lysis Buffer (CCLR) following 
manufacturer's instructions (Promega). Luciferase assays were performed according to 
the manufacturer's instructions (Promega) using 10 ul of protein extract in 50 ul of 
luciferase assay buffer. A Turner Designs 20/20 luminometer was used under the 
following conditions: 2 seconds of delay time, 10 seconds of integrate time, and the 
mode was set to Standard. Two to three independent experiments were performed in 
duplicate and expressed as mean + standard deviation. Significance was determined by a 
P-value < 0.05 using a two-tailed Student's T-test. 
Analysis of Protein Expression Levels 
Bradford Assays 
Protein concentrations were determined using Biorad's Bradford reagent assay 
according to the manufacturer's instructions. Experiments were performed in duplicate 
and averaged for final concentration. 
Western Blot Analysis 
For western blot analysis, cells were harvest in 600 ul of Tris/SDS Buffer (30 mM 
Tris, 1% SDS). Protein concentration was determined by Bradford assays as described 
above, equal concentrations of protein were resuspended in 5X SDS-PAGE loading dye 
(25% glycerol, 5% SDS, 125 mM Tris, pH 6.8, 0.004% Bromophenol Blue), and boiled 
for 5 minutes. Proteins were separated according to their molecular weight through a 
12.5% SDS-PAGE gel at 10 mAmps overnight. To assess molecular weight, 10 ul of 
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rainbow high molecular weight marker was added for each gel (Amersham). Separated 
proteins were transferred to nitrocellulose membranes through a semi-dry transfer 
cassette at 134 mAmp for 1 hr and 30 minutes at room temperature. The following 
electroblotting buffers were used: Anode Buffer #1 (0.3 M Tris, pH 10.4, 20% 
Methanol), Anode Buffer #2 (25 mM Tris pH 10.4, 20% Methanol) and Cathode Buffer 
(25 mM Tris pH 9.4, 40 mM 6-Aminohexanoic Acid, 20% Methanol). The membrane 
was washed in IX PBS (137 mM NaCl, 2.68 mM KC1, 1.47 mM KH2P04, 7.81 mM 
NaHPC>4) for 5 minutes after the transfer. The membrane was blocked overnight in 5% 
nonfat milk (diluted in PBS) to prevent nonspecific binding to the membrane. The 
membrane was then washed four times in IX PBS plus 0.1% Tween (PBST, 5 
minutes/wash) and the primary antibody was added at the specified dilutions and 
incubated for 1 hour at room temperature. For detection of the MIE proteins, we used a 
1:2000 dilution of the MAB810 monoclonal antibody (Millipore, 1 mg/ml). For 
detection of actin as control for cell number, we used a 1:1000 dilution of actin antibody 
A1978 (Sigma). The membrane was washed four times for 5 minutes in PBST. The 
secondary antibody was diluted 1:15000 in 5% milk and incubated 1 hour at room 
temperature. The following secondary antibodies were used: IRDye 800CW goat, anti-
mouse IgG and IRDye 680 goat, anti-Rabbit IgG (Licor). The membrane was washed 
four times for 5 minutes in PBST. Proteins were detected using the Odyssey Infrared 
Imaging (Licor) according to the manufacturer's instructions. 
37 
Analysis of RNA expression in Transient Transfected Cells 
RNA Isolation 
To determine RNA expression levels, primary fibroblasts cells were transfected 
with 10 jxg of total DNA by the DEAE-dextran transfection as described above. Samples 
were harvested 48 hours post-transfection using RNeasy kit (Qiagen) according to the 
manufacturer's instructions. During purification, RNA was treated with DNAse I using 
Qiagen's DNAse I Kit according to manufacturer's instructions for on-column digestion 
and resuspended in RNase-free water. RNA concentration and quality were determined 
by 260 and 280 nm absorbance readings. 
First Strand cDNA Synthesis 
Superscript III first strand synthesis supermix kit (Invitrogen) was used to 
generate cDNA for real time PCR using 1-5 (xg of total RNA primed with 250 ng of 
random hexamers according to the manufacturer's instructions. 
Real-Time PCR 
cDNA and DNA levels were assayed by Real time PCR using iQ SYBR green 
supermix (Invitrogen) in a total of 25 ul, containing 12.5 ul of mastermix, 300 nM of 
specific primers, and 1-5 ul of cDNA. Primers used to amplify the IE2 and GAPDH 
genes have been previously described (149). Real time PCR reactions were performed 
with a Biorad iCycler system using the standard curve method of quantification. Each 
PCR was performed as follows: initial uracil DNA glycosylase decontamination at 50°C 
for 2 min, a 2 min hot-start denaturation at 95 °C, and 39 amplification cycles (15 s at 
38 
95°C, 30 s at 60°C). Melting Curve analysis was performed to ensure the specificity of 
PCR product and lack of primer-dimer artifacts. The melting temperature of the final 
double-stranded DNA products was determined by gradual heating from 55°C to 95°C 
for 80 cycles with a 0.5°C increase after each cycle. 
Quantification of DNA andRNA by Real Time PCR 
The PFAFFL mathematical model was used for quantification of real time PCR 
reactions (106). Briefly, G6PD-TOPO and IE2-TOPO plasmids were used to generate 
standards for calculation of PCR efficiencies for each primer set. Serial dilutions of the 
plasmids from 10 to 10 copies were used for determination of the PCR efficiency for 
each primer set. Each reaction was performed in duplicate and error bars reflect standard 
deviations within each experiment. Significance was determined by a P-value < 0.05 
using a two-tailed Student's T-test. The ratio of target gene mRNA expression relative to 
the internal control was calculated as described in (106) using the following equation 
(where E is the efficiency of real time PCR amplification for the specified gene): 
fr> \ ACt target (wildtype - mutant) 
V-'target,' 
Relative Expression = 
re \ ACt reference (wildtype - mutant) 
M-referenceJ 
In this equation, target represents the gene of interest (IE2) and reference represents the 
internal reference gene or calibrator (G6PD). 
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Results 
Mutations in IE2 Inhibit Early Gene Activation 
Previous studies in our laboratory identified a region of IE2 at amino acid 540 that 
when mutated by insertion of a linker coding for 4 amino acids resulted in both loss of 
MIE promoter repression and UL54 activation (134). However, a study in 2007 
demonstrated that a double mutation at P535A/Y537A in IE2 inhibited gene activation of 
viral early promoters, but not repression of the MIE promoter, suggesting separation of 
the IE2 transactivation and autoregulation functions (105). To more closely address the 
discrepancies between these two studies and uncover regions of IE2 important in 
transcriptional regulation, we generated single amino acid mutations in IE2 between 
amino acid 535 and 545 using site directed mutagenesis as described in Materials and 
Methods. Amino acids were mutated to either an Alanine, or Valine, because these 
residues are structurally neutral, thereby reducing steric or electrostatic effects. We chose 
to analyze UL54 and UL112-113 transcriptional activation due to the fact that these 
promoters are required for HCMV infection and are well-characterized in the literature. 
Primary fibroblasts were co-transfected with a luciferase reporter plasmid containing the 
luciferase gene upstream of the UL54 or UL112-113 early promoters and an IE2 
expression construct in a pSVHk vector by DEAE-dextran transfection (Fig. 8 and 9). 
The pSVHk vector contains genomic DNA from the entire UL122-123 region (under the 
control of the MIE promoter) with single amino acid mutations in the C-terminus of IE2. 
As a control, luciferase constructs were co-transfected with an empty vector, indicative of 
basal levels of promoter activation. We found that mutations at 
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Regulation of the UL54 Promoter 
100<H 
FIG. 8. Mutations in IE2 inhibit UL54 promoter activity. The pPol-Luc reporter 
construct was co-transfected into primary fibroblasts with IE2 wildtype or mutant 
expression plasmids in pSVHk vector. The pSVHk plasmid contains the UL122-123 
genomic region, expressing the MIE proteins under the control of the native MIE 
promoter. Cells were harvested for luciferase activity 48 hours after transfection. 
Luciferase assays were performed in duplicate with 2-3 independent experiments and 
luciferase activity was expressed as mean ± SD. An asterisk (*) indicates statistically 
significant difference (P<0.05), wildtype versus mutant IE2. 
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Regulation of the UL112-113 Promoter 
1000q 
FIG. 9. Mutations in IE2 inhibit UL112-113 promoter activity. The pULl 12-113-Luc 
reporter construct was co-transfected into primary fibroblasts with IE2 wildtype or 
mutant expression plasmids in pSVHk vector. The pSVHk plasmid contains the UL122-
123 genomic region, expressing the MIE proteins under the control of the native MIE 
promoter. Cells were harvested for luciferase activity 48 hours after transfection. 
Luciferase assays were performed in duplicate with 2-3 independent experiments and 
luciferase activity was expressed as mean ± SD. An asterisk (*) indicates statistically 
significant difference (P<0.05), wildtype versus mutant IE2. 
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amino acids 535, 536, 537, 543 and 544 significantly downregulated luciferase 
expression from the UL112-113 and UL54 promoters when compared to wildtype IE2. 
Interestingly, a mutation at amino acid 541 demonstrated a significant decrease in UL54 
activation but not UL112-113 activation. It is unlikely that the results we observe in 
transcriptional regulation are due to structural instability since other mutations in IE2 
between amino acids 538 to 542 had minimal effects on early gene regulation. These 
results are consistent with previous reports suggesting that amino acids in this region of 
IE2 are important for transcriptional regulation of early genes. However, the results of 
the analysis of the mutation at Threonine 541 demonstrate that a single amino acid 
mutation may have distinct effects on early gene activation at different promoters. 
Mutations in IE2 Alleviate IE2-Mediated Autorepression 
IE2 is able to autoregulate its own expression by binding to the CRS of the MIE 
promoter. To determine whether IE2 mutant proteins unable to regulate early gene 
transcription also lose IE2 autoregulatory functions, we investigated the effects of 
mutations in IE2 on MIEP autorepression by luciferase assays as described above. We 
do not see repression of the MIE promoter with the wildtype (WT) IE2 since other MIE 
proteins are present to balance MIE promoter regulation. Mutations at 535, 536, 537, 543 
and 544 resulted in significantly higher levels of MIE promoter activation when 
compared to wildtype IE2, suggesting a loss in IE2 auto-repressive properties (Fig. 10). 
The mutation at amino acid T541A resulted in a slight, but not significant, increase in 
MIEP activity. These results suggest that mutations which disrupt the transactivation of 
the UL112-113 and UL54 promoters are likely to disrupt the ability of IE2 to 
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FIG. 10. Mutations in IE2 relieve alleviate MIE promoter repression. The pMIEP-Luc 
reporter construct was co-transfected into primary fibroblasts with IE2 wildtype or 
mutant expression plasmids in pSVHk vector. The pSVHk plasmid contains the UL122-
123 genomic region, expressing the MIE proteins under the control of the native MIE 
promoter. Cells were harvested for luciferase activity 48 hours after transfection. 
Luciferase assays were performed in duplicate with 2-3 independent experiments and 
luciferase activity was expressed as mean ± SD. An asterisk (*) indicates statistically 
significant difference (P<0.05), wildtype versus mutant IE2. 
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autoregulate the MIEP. However, the IE2 mutation at T541A emphasizes the fact that 
individual promoters may be regulated through different mechanisms by IE2. 
Inhibition of Viral Gene Regulation is Specific for the IE2 Gene Product 
The IE2 gene product is expressed as a splice variant from the UL122-123 gene 
region of HCMV. The MIE gene region encodes a number of additional splice variants, 
including the IE1 protein (132, 136). To determine effects specific for the IE2 protein, 
luciferase assays were performed by co-transfection of IE2 wildtype and mutant 
expression plasmid in a pMCRS86 vector with luciferase reporter constructs under the 
control of the UL112-113 or UL54 promoters. The pMCRS86 vector expresses the IE2 
cDNA under the control of a mutated MIE promoter designed to prevent autoregulation 
of the transfected plasmid. We chose to continue analysis with only the P535A and 
Y544A mutants since these mutants displayed similar transcriptional regulatory patterns 
although the physical mutations are distinct from one another. Consistent with studies in 
the context of the entire genomic region, mutations in IE2 at amino acids 535 and 544 
impaired transcriptional regulation of the MIE, UL54 and UL112-113 promoter between 
9- and 62-fold in the absence of other viral gene products (Fig. 11). These results 
confirm that the effects observed in transcriptional regulation of the MIE and early 
promoters with these two mutations are specific for the IE2 protein. 
Mutations in IE2 Lead to increased IE2 RNA and Protein Expression 
Differences observed in promoter regulation by the IE2 mutant protein may be 
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IE2 Regulation in the Absence of MIE Proteins 
FIG. 11. Regulation of HCMV promoters by IE2 mutants in absence of other MIE 
proteins. The pMIEP-Luc, pPol-Luc or UL112-112 reporter constructs were co-
transfected into primary fibroblasts with IE2 wildtype or mutant expression plasmids in 
the pMCRS86 vector. The pMCRS86 plasmid expresses IE2 cDNA under the control of 
a MIE promoter with mutations in the CRS to prevent autoregulation to IE2. Cells were 
harvested for luciferase activity 48 hours after transfection. Luciferase assays were 
performed in duplicate with 2-3 independent experiments and luciferase activity was 
expressed as mean ± SD. An asterisk (*) indicates statistically significant difference 
(P<0.05), wildtype versus mutant IE2. 
46 
due to variations in the amount of IE2 RNA and protein present in the cell. In addition, 
loss of activation or autorepression may be due to decreased levels of the mutant IE2 
protein. To exclude these possibilities, accumulation of IE2 RNA and protein levels in 
transfected cells was determined by real time (RT)-PCR and western blot analysis, 
respectively. Our results demonstrate that mutations in IE2 lead to increased levels in 
IE1 and IE2 mRNA levels compared to wildtype, consistent with loss of autoregulation, 
as shown in Fig. 12. Western blot analysis coincided with mRNA expression showing 
increased protein accumulation of the IE1 and IE2 gene products in primary fibroblast 
(Fig. 13). These observations confirm our previous results indicating that IE2 mutations 
at amino acids 535 and 544 disrupt autoregulation of the MIEP and, subsequently, result 
in increase levels of IE2 (and IE1) RNA and protein levels. 
Discussion 
The goal of specific aim 1 in this dissertation was to identify regions of IE2 
important in transcriptional regulation of viral gene promoters. Previous studies 
identified a region in IE2 at amino acid 540 important in both repression of the MIEP and 
activation of the UL54 promoter mutated by linker insertion (134). More recently, Petrik, 
et al. determined that a double mutation at amino acid 535 and 537 resulted in changes to 
' IE2- mediated activation of UL4 and UL112-113 early gene promoters (105). However, 
in this study, the authors were unable to uncover any changes to regulation of the MIE 
promoter, concluding that the domains involved in autoregulation and transactivation of 
the IE2 do not overlap (105). Although these results are contradictory in respect to 
functional domains in the IE2 C-terminus, they emphasize the importance of this region 
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IE2 mRNA Expression 
FIG. 12. Mutations in IE2 increase IE2 mRNA expression in transient assays. Primary 
fibroblasts were transfected with 10 ug of wildtype or mutant IE2 expression plasmids in 
the pSVHk vector. The pSVHk plasmid contains the UL122-123 genomic region, 
expressing the MIE proteins under the control of the native MIE promoter. Total RNA 
was harvested at 48 hours post transfection, reverse transcribed to cDNA and expression 
levels were determined by real time PCR. Real time PCR analyses were performed in 
duplicate and relative expression was expressed as mean ± SD. 
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Actin 
FIG. 13. Mutations in IE2 increase protein expression in transient assays. Primary 
fibroblasts were transfected with 10 ug of wildtype or mutant IE2 expression plasmids in 
the pSVHk vector. The pSVHk plasmid contains the UL122-123 genomic region, 
expressing the MIE proteins under the control of the native MIE promoter. Total protein 
was harvested at 48 hours post transfection and separated on a 12.5% SDS-PAGE. 
Western blot analysis was performed using antibodies to the MIE proteins and actin. 
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in transcriptional regulation of HCMV promoters. 
Potential Effects of Single Amino Acid Mutations 
Several studies have sought to investigate functional domains of IE2 important in 
transcriptional regulation of early viral genes. Many of these studies have approached 
this problem using IE2 mutant protein contain more than one amino acid mutation or 
large deletions. In this study, we have used single amino acid mutations to determine the 
effects of mutations in the C-terminus of IE2 on transcriptional regulation. It is not 
unexpected for single amino acid mutations in the C-terminus of IE2 to have the ability to 
significantly alter protein function. Three-dimensional modeling of the IE2 C-terminus 
suggests that this region is dynamic in structure and may be altered by subtle changes in 
the protein sequence (5). 
The region between amino acids 535 and 545 of HCMV is highly conserved 
among different species of CMV, especially at amino acids 535, 536, 537 and 544 (Fig. 
7). Mutations at these highly conserved amino acids disrupted transactivation of viral 
early promoters and autoregulation of the MIE promoter. In addition, the mutations at 
amino acids 535 and 544 led to increased mRNA and protein levels of mutant HCMV 
proteins. These results suggest that these residues are critical for IE2 function. It is 
important to note that increases that mRNA level increases are much higher than the 
increase in IE2 protein levels with the mutation at amino acid 535. This result suggests 
that IE2 protein may be degraded with mutations in IE2 and will be evaluated in future 
studies using assays such as pulse-chase experiments. 
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IE2 Transactivation and Autoregulatory Domains Overlap 
In order to address the discrepancy in the location of IE2 functions domains 
involved in transcriptional regulation, IE2 recombinant proteins were generated 
containing single amino acid mutations at amino acids 535 to 545 to either an Alanine or 
Valine residue. Luciferase assays were used to determine the ability of mutated IE2 to 
activate early viral gene promoters, UL54 and UL112-113, or repress the MIE promoter 
in transient assays. The IE2 protein was expressed either in the context of the UL122-
123 gene loci where other MIE gene products were all co-expressed or IE2 cDNA was 
expressed under the control of a mutated MIE promoter. The results presented in Fig. 12 
demonstrate that a number of the mutations generated between amino acids 535 and 545 
resulted in both a loss of IE2 autoregulatory and transactivation properties in primary 
fibroblasts when functioning in the presence of other MIE proteins. 
In this dissertation, we have focused on the IE2 mutations at amino acid 535 and 
544. The P535A and Y544A mutations lead to a significant decrease in activation of 
both the UL54 and UL112-113 promoters. This result was consistent in both the 
presence and absence of other MIE proteins. In addition, both mutations also resulted in 
loss of repression of the MIE promoter in the presence and absence of other MIE 
proteins. These results support Stenberg, et al. suggesting the IE2 domains involved in 
transcriptional activation and repression overlap each other (134). 
The MIE gene region encodes for a number of splice variants. In order to 
determine if mutations in the IE2 gene affect viral gene regulation, cells were 
cotransfected with an IE2 plasmid expressing IE2 cDNA and luciferase reporter 
construct. Our results confirm that the effects observed in transcriptional regulation of 
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the MIE and early promoters with these two mutations are specific for the IE2 protein 
and result in similar phenotypes of transcriptional regulation (Fig. 11). 
The T541A Mutant Differentially Regulates Early Gene Promoters 
In our studies, we observed that a single amino acid mutation at T541A resulted 
in distinct effects on early gene activation at different promoters. Specifically, while the 
mutation at amino acid 541 has no effect on UL112-113 activation or MIE promoter 
repression, this mutation leads to a significant decrease in UL54 activation in vitro. In 
the AD 169 laboratory strain of HCMV, the amino acid 541 is originally an Alanine 
residue (5). In addition, in other CMV species this amino acid is typically an Alanine or 
Valine residue (Fig. 7). This suggests that reversion of this amino acid from a Threonine 
to an Alanine restores this residue to a more conserved amino acid residue. The two 
early promoters studied in this dissertation are regulated by two different mechanisms. 
The UL54 promoter is primarily regulated by cellular and viral transcription factors (59, 
61, 62, 81). The UL112-113 promoter is regulated by nonessential DNA binding of IE2 
in addition to transcription factors. Unfortunately, the exact mechanism(s) of IE2 
transcriptional regulation remains unclear. In addition, due to the numerous functional 
properties available to IE2 for transcriptional regulation, it is likely that individual 
promoters require separate and overlapping functions for efficient activation. To obtain a 
more comprehensive understanding of how individual promoters are regulated, 
exploration of this mutation in IE2 will be the focus of future studies. 
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Summary 
Our results suggest that mutations which disrupt the transactivation of the UL112-
113 and UL54 promoters are likely to disrupt the ability of IE2 to autoregulate the MIEP. 
These results are consistent with previous studies in our laboratory which suggest that the 
domain involved in IE2 activation of the UL54 promoter overlaps the domain required 
for repression of the MIE promoter. In addition, mutations in IE2 which prevented 
regulation of the MIE promoter, also led to increased levels of RNA and protein 
expression. Overall, these results are consistent with our hypothesis that single amino 
acid mutations within IE2 are able to alter transcriptional regulation of HCMV immediate 
early and early gene promoters. 
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CHAPTER IV 
MUTATIONS IN IE2 INHIBIT REPLICATION AND TRANSCRIPTIONAL 
REGULATION OF VIRAL PROMOTERS DURING HCMV INFECTION 
Introduction 
Expression of the HCMV IE2 protein is required for virus replication and 
activation of essential viral genes (45, 74, 86, 107, 109, 134). Our data in transient assays 
supports a model where mutations in IE2 at amino acid 535 and 544 result in loss of both 
IE2 transactivation and autoregulatory functions. Since the IE2 protein with mutations at 
these amino acids is no longer able to activate promoters essential for virus DNA 
replication in transient assays, we hypothesize that these mutations will disrupt the ability 
of IE2 to activate early promoters during infection and prevent HCMV replication. 
Due to the difficulty in generating recombinant virus mutated in an essential gene 
most of the structure-function studies of IE2 have been performed in transient 
transfections (3, 14, 57, 62). In order to circumvent the difficulties in mutational analysis 
of essential HCMV genes, more recent studies have employed the use of HCMV bacterial 
artificial chromosomes (BACs) to evaluate mutations in the context of the genome (1,9, 
92, 143). Although laboratories have been able to successfully generate recombinant 
viruses from HCMV BACs mutated in IE2, lack of complementary characterization of 
the mutant IE2 protein in vitro have made these analyses difficult to interpret (45, 117, 
149). 
BACs are able to stably maintain up to 300 kilobasepairs of DNA, allowing 
genetic cloning of the large HCMV genome. The HCMV BAC contains the HCMV viral 
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genome, a bacterial selectable marker and an origin of replication (ori) to allow 
propagation of the DNA in bacteria. Mutagenesis of these BAC constructs require 
several considerations, including awareness of the BAC vector sequence, source of the 
mutated DNA sequence, and the method of recombination (reviewed in (1, 143)). 
The strategy used in this dissertation is based on the Red system of recombination 
mediated by the cl-recombination proteins, exo, bet and gam (155). DY380 E. coli cells 
contain a defective cl-prophage carrying the cl-recombination genes under the control of 
the temperature-sensitive I-cI857 repressor (71). Cells are incubated at 42°C allowing 
inactivation of the cl repressor and production of the cl-recombination proteins to 
produce recombination-competent cells. The HCMV BAC construct utilized and 
modified in this dissertation uses Cre-mediated loxP recombination to remove the 
backbone of the BAC DNA and remove the antibiotic gene inserted for screening the 
modified BAC construct. 
Characterization of mutations in IE2 within the context of the viral genome is 
important in order to verify the results seen in transient transfections. Several studies 
have shown that results demonstrated by transient transfections may not necessarily 
reflect processes that occur during virus infection. For example, the modulator region of 
IE2 is located upstream of the CRS and contains binding sites to YY1 (48, 78, 97, 124). 
i 
Transient studies show that this region is important in autoregulation of the MIEP (48, 
78, 97, 124). However, deletion of the modulator region in recombinant viruses does not 
alter transcription of the MIE gene products (89). Another example is found in the 
functional analysis of the ICPO, an HSV-1 IE protein. Transient assays demonstrate that 
ICPO alone is able to induce ICP8 mRNA (112). However, when assessed in the viral 
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genome, ICPO appears to have little effect on ICP8 mRNA expression (26). These studies 
emphasize differences between transient assays and characterization of promoter 
regulation in the context of a viral infection 
In order to investigate transcriptional regulation of viral promoters in the context 
of a viral infection, we took the following three approaches. First, recombinant HCMV 
BACs containing mutations in IE2 were generated using homologous recombination and 
confirmed by several approaches as described in Materials and Methods. Second, 
recombinant BAC DNA was transfected into primary fibroblasts and evaluated for the 
ability to produce infectious virus. Third, recombinant BAC DNA was transfected into 
primary fibroblasts and assessed for IE2-mediated activation of IE and early genes. 
These experiments provide a more biologically relevant understanding of the role of IE2 
in transcriptional regulation of viral genes and replication within HCMV infected cells. 
Materials and Methods 
Plasmids used for generation and analysis of HCMV BACs 
IE2 Plasmids 
Mutagenesis of IE2 in the pSVHk and pMCRS86 constructs was achieved using 
Stratagene's Site-directed PCR mutagenesis kit XL according to the manufacturer's 
instructions and using a PCR extension time of 7 minutes. The following primer 
sequences were used (mutations in IE2 are underlined, only forward primer is shown): 
P535Af-3, GTG GGT TCA TGC TGG CGA TCT ACG AGA CGG, and Y544A-2, CCA 
CGA AGG CCG CGG CCG TGG GGC. 
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Generation ofHCMVBACs 
To generate pIE2-Zeo-TOPO for homologous recombination with the HCMV 
BAC, the Zeocin gene was first amplified from pCMV/Zeo (Invitrogen) using BamHI-
LoxP-Zeo-LoxP-Bglll forward and reverse primers: 5'-AGA TCT ATA ACT TCG TAT 
AGC ATA CAT TAT ACG AAG TTA TGG AAC GGA CCG TGT TGA C-3' and 5'-
GGA TCC ATA ACT TCG TAT AGC ATA CAT TAT ACG AAG TTA TCA AGT 
TTC GAG GTC GAG GTG-3', respectively (BamHI and Bglll recognition sites are 
underlined). These primers add a BamHI and LoxP site to the 5' end and a Bglll and 
LoxP site to the 3' end. This fragment was then cloned into pCR4-TOPO according to 
the manufacturer's instructions (Invitrogen) to generate pZeo-TOPO. Subsequently, the 
IE2 fragment was PCR amplified from pMCRS86 using PstI-435-IE2-579-BamHI 
primers which amplifies the IE2 region between amino acid 435 and 579 adding a PstI 
site next to aa435 and a BamHI site after 579. The forward and reverse PstI-435-IE2-
579-BamHI primers are 5'-CTG CAGAAC CTG GCC CTC TCC ACT C-3' and 5'-GGA 
TCC ACT TAC TGA GAC TTG TTC CTC AGG TCC-3', respectively (PstI and BamHI 
recognition sites are underlined). This PCR fragment was then subcloned into pCR4-
TOPO to generate pIE2-TOPO. pIE2-Zeo-TOPO was generated by cloning the IE2 
fragment of pIE2-Zeo into the pZeo-TOPO construct using PstI and BamHI restriction 
enzyme digestion. 
Real Time PCR 
IE2-TOPO and G6PD-TOPO plasmids were generated by PCR amplification and 
TOPO cloning as previously described. 
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Mammalian Cells 
Primary human foreskin fibroblasts (HFF) were grown and maintained as 
previously described in Chapter 3. 
Molecular Cloning and Generation of Plasmid DNA 
Molecular cloning techniques and generation of plasmid DNA were performed as 
previously described in Chapter 3. 
Generation of HCMV BACs 
Generation of the Exon5 Deletion BAC 
The Exon5 Deletion BAC was generated by PCR amplification of the kanamycin 
resistance marker from pGEM-oriV/kan-1 (kindly provided by Hua Zhu, University of 
Medicine and Dentistry of New Jersey, Newark, NJ) using the following Exon5_449-
Kan-580 forward and reverse primers containing sequence homology to the kanamycin 
gel and a 20 bp overhang with homology to the C-terminus of IE2 between amino acids 
449 and 579: 5' CCA TGG CCC TCT CCA CTC CCT TCC TCA TGG AGC ACA CCA 
TGG CTC TTG TTG GCT AGT GCG TA 3' and 5' CAC TAT GTA CAA GAG TCC 
ATG TCT CTC TTT CCA GTT TTT CTC TGC CAG TGT TAC AAC CAA 3'. This 
PCR fragment was gel-purified and transformed into electro- and recombination-
competent DY380 cells containing the HCMV Towne-BAC to generate the HCMV 
AExon5 BAC. Positive clones containing successful deletion of the amino acids 449 to 
579 and replacement of this region with the kanamycin resistance marker were confirmed 
by growth on LB agar plates containing kanamycin and chloramphenicol, PCR analysis 
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and restriction enzyme digestion. 
Generation of the HCMV wildtype-reverent and mutant BA Cs 
The IE2 Wildtype-Revertant and mutant BACs were generated by PCR 
amplification of wildtype or mutant IE2-Zeo-TOPO (described previously) using the 
following Exon5 449-Kan-580 Repl forward and reverse primers containing IE2 
overhangs with sequence homology to the HCMV IE2 region flanking amino acid 544 to 
579: 5' CAA CCT GGC CCT CTC ACT CCC TTC CTC ATG GAG CAC ACC ATG 
CCC GTG ACA CAT 3' and 5' CGG GGA ATC ACT ATG TAC AAG AGT CCA TGT 
CTC TCT TTC CAG TTT TTC AGA TCT ATA ACT TCG TAT AAT G 3'. This PCR 
fragment was gel-purified and transformed into electro- and recombination-competent 
DY380 cells containing the HCMV AExon5 BAC. Positive clones were confirmed by 
growth on LB agar plates containing zeocin and chloramphenicol, PCR analysis, southern 
blot analysis and restriction enzyme digestion. 
BAC Cloning and Manipulation 
Generation of Electro-competent and Recombination-competent DY380 cells for 
Transformation and Propagation of BAC DNA 
For preparation of electro- and recombination-competent DY380 cells for BAC 
transformations, an overnight culture of DY380 cells (with or without BAC construct) 
was inoculated from a single colony into 5 mis of LB media with appropriate antibiotic. 
The following day, 100 mis of LB was inoculated with 5 mis of the overnight culture 
(1:20) and grown at 32°C to an OD600 of 3.5-4.0. In order to prepare recombinant-
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competent cells, bacteria were incubated at 42°C in a water bath with shaking for 10 
minutes. Cells were then chilled on ice for 30 minutes. The cells were centrifuged at 
4,000 X g for 15 minutes at 0°C. The supernatant was then removed and the cells were 
re-suspended in 100 mis of ice cold sterile water. This wash was repeated two more 
times. Cells were then re-suspended in 10 mis of 10% glycerol and spun at 5,000 X g for 
15 minutes at 0°C. Last, cells were re-suspended in 300 ul of 10% glycerol, separated 
into 40 |al aliquots, and stored in -80°C (or used immediately for electroporation). 
Transformation ofBAC DNA 
For transformation of BAC DNA into electro-competent DY380 cells, cells were 
first thawed on ice. Approximately 200 ng of DNA was incubated with thawed cells for 
and mixed gently with a pipette tip. Cells plus DNA were transferred to a 0.1 cm 
electroporation cuvette and pulsed at 1.6 kV, 25 uF with pulse controller of 200 Q using 
a Gene Pulser XCell Electroporation System (Biorad). Following electroporation, 1 ml 
of LB media was added to each cuvette and transferred to a round bottom polypropylene 
tube. Cells were incubate at 32°C for 1 hour without shaking, then transferred to a 1.5 ml 
eppendorf tube and centrifuged at maximum speed for 1 minute. Last, cells were 
resuspended into 0.1 ml of LB media and plated on LB agar containing the appropriate 
antibiotic. 
DNA Amplification and Purification from Bacterial Cells 
For amplification of BAC DNA, a 5 ml overnight culture was grown in LB with 
the appropriate antibiotic. The following day, the overnight culture was centrifuged for 5 
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min at 5000 X g. DNA was isolated as described in Copeland, et al. with slight 
modifications (147). Briefly, the supernatant was removed and the pellet was 
resuspended in 250 ul of Buffer PI with RNase (Nucleobond). The cells were incubated 
for 5 minutes at RT. After the 5 minute lysis, 250 ul of Buffer P2 was then added for 5 
minutes at RT, followed by 250 ul of Buffer N3 for 5 min on ice. Cells were centrifuge 
at 6,000 X g for 5 min at RT. The supernatant was transferred to a new tube and the 
centrifugation was repeated at 6,000 X g for 5 min at RT. The supernatant was 
transferred to a new tube and 750 ul of isopropanol was added to the supernatant. The 
solution was mixed by inversion and incubated on ice for 10 min. Cells were centrifuged 
at 6,000 X g for 10 min at 4°C. The supernatant was decanted and the pellet was washed 
in 500 ul of 70% ethanol. The sample was centrifuge at 14,000 X g for 5 min at 4°C. 
The supernatant was decanted and pellet was allowed to air dry for at least 10 min. The 
pellet was then resuspended in 50 ul of TE. 
Following confirmation of small scale cultures in BAC DNA, the 5 ml overnight 
culture was diluted 1:1000 and grown overnight in 250 mis of LB with the appropriate 
antibiotic. Two 250 ml cultures were combined and centrifuged at 6,000 X g for 15 
minutes and the supernatant was removed. Large scale DNA purifications were 
performed using Clontech's Nucleobond BAC 100 kit according to the manufacturer's 
instructions. 
Confirmation of HCMV BAC DNA 
Southern Blot Analysis ofHCMVBACs 
To confirm that generation of HCMV BAC DNA did not result in any large scale 
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rearrangements of the genome, DNA was assessed by southern blot analysis. First, 5 ug 
of BAC DNA was digested with Smal restriction enzyme overnight and separated on a 
1.0% agarose gel. DNA fragments were visualized by ethidium bromide staining and 
transferred onto a Hybond nylon membrane (Amersham) overnight by capillary methods. 
The membrane was then baked for two hours at 80°C in a vacuum oven. The following 
primers were used to amplify IE2 from the pSVHk vector: 86P449_FSouthern, CCC 
GTG ACA CAT CCA CCC AAA GTG, and 86E579_RSouthern, CTG AGA CTT GTT 
CCT CAG GTC CTG G. To generate a probe for IE2, the PCR product was DIG-labeled 
using the DIG High Prime Starter Kit according to the manufacturer's instructions 
(Roche) and quantitated by dot blot analysis. The DNA membrane was hybridized 
overnight with labeled probe, washed to remove non-specifically bound probe, and 
detected by anti-DIG antibody followed by CPSD staining according to the 
manufacturer's instructions. Membrane was exposed to X-ray film for 15-25 minutes at 
room temperature. 
Confirmation of BAC DNA by restriction enzyme digestion 
In order to confirm that no large scale deletions or mutations had occurred to the 
BAC DNA during mutagenesis, BAC DNA was digested with appropriate restriction 
enzymes. Digestion was performed as previously described for plasmid DNA in Chapter 
3 with the following exception: approximately 1 ug of BAC DNA was digested with 10-
20 units of enzyme for 16-18 hours. 
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Confirmation ofBAC DNA by PCR analysis 
The following primers were used for confirmation of HCMV BAC constructs 
within the IE2 gene, Downstream IE2 Primer Forward, 5' GAT GTC TCG CAG GGT 
GGG TAG ATG 3', Upstream IE2 Primer Reverse, 5' GCA TGT TCC GCA ACA CCA 
ATC G 3', Internal IE2 Primer Forward, 5' AAG ACC TGG ACA CCC TGA GCC TG 
3', and Internal IE2 Primer Reverse, 5' CAG GCT CAG GGT GTC CAG GTC TTC 3'. 
Sequencing of BAC DNA 
To confirm that manipulations of BAC DNA did not alter the nucleotide sequence 
and/or generated the designed mutations, sequencing of the mutated region was 
performed using BigDye Terminator v3.1 Cycle Sequencing kit according to the 
manufacturer's instructions for analysis of BAC DNA. Sequencing was performed by an 
ABI Primer 3130 Genetic Analyzer. Sequencing of the IE2 gene was confirmed using 
the sequencing primers described previous for sequencing of plasmid DNA. 
Transfections of BAC DNA 
For BAC transfections in primary fibroblasts, 10 fig of BAC DNA and 1 fj.g of 
pp71 DNA was transfected into HFF by the calcium phosphate method. Cre 
Recombinase (1 jag) was transfected with BACs in DNA and virus replication assays 
(86). Media was changed every 4-5 days until plaque outgrowth occurred. Cells were 
monitored for 3 or more weeks for plaque formation. 
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Growth of Recombinant Viruses 
Harvesting Reconstituted Virus 
Following BAC transfections into primary fibroblasts, reconstituted virus was 
harvested from the supernatant of BAC transfected cells when 90-100% of cells 
displayed cytopathic effects (CPE) and stored at -80°C. 
Generation of Virus Stocks 
For generation of virus stocks, supernatant from BAC transfected cells were 
thawed at room temperature, diluted in DMEM media at 1:1000, and used to inoculate a 
T150 flask of primary fibroblasts at 100% confluency. Cells were incubated at 37°C for 
two hours. After two hours, inoculum was removed and new media was added. Cells 
were monitored daily for CPE and supernatants were harvested at 100% CPE. Media 
was changed every 5 days. 
Titering of Virus Stocks 
To determine the concentration of virus stocks, serial dilutions were generated 
and used to inoculate individual wells within 6-well plates containing primary fibroblasts 
at 100% confluency. Cells were incubated at 37°C for two hours, followed by an overlay 
with 1% agarose, 2X MEM, and 1% penicillin-streptomycin. Cells were monitored daily 
for plaque formation and a new overlay was added every 5 days. The following equation 
was used to determine virus stock concentration in plaque forming units (pfu)/ml of 
supernatant: 
Number of plaques 
pfu/ml = 
D * V 
64 
In this equation, D is the dilution factor and V is the volume of diluted virus added to 
each well. 
Analysis of Nucleic Acid Expression 
TriZol extractions ofRNA, DNA and protein 
Primary fibroblasts were transfected with approximately 10 jxg of HCMV BAC 
DNA and 1 jag of HA-pp71 by calcium phosphate transfection as described above. 
Samples were harvested at various times postinfection using Trizol reagent (Invitrogen) 
according to the manufacturer's instructions. During purification of RNA, isolated RNA 
was treated with DNAse I using Qiagen's DNAse I Kit according to manufacturer's 
instructions. DNA and RNA concentration and quality were determined by 260 and 280 
nm absorbance readings. 
First Strand cDNA Synthesis 
Superscript III first strand synthesis supermix kit (Invitrogen) was used to 
generate cDNA for real time PCR using 1-5 jag of total RNA primed with 250 ng of 
random hexamers according to the manufacturer's instructions. 
Real-Time PCR 
cDNA and DNA levels were assayed by Real time PCR using a SYBR green Real 
time PCR kit (Applied Biosystems) as previously described. 
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Quantification ofDNA and RNA by Real Time PCR 
Plasmids containing the UL54-CAT promoter, GAPDH promoter, IE2 gene, and 
G6PD gene were used to generate standard curves to quantitate relative amounts of 
cDNA in each sample. Serial dilutions of the plasmids from 10 to 10 copies were used 
for determination of the PCR efficiency for each primer set. Each reaction was 
performed in duplicate and error bars reflect standard deviations. Significance was 
determined by a P-value < 0.05 using a two-tailed Student's T-test. The ratio of target 
gene mRNA expression relative to the internal control was calculated as described in 
(106) using the following equation (where E is the efficiency of real time PCR 
amplification for the specified gene): 
/TJ \ACt target (wildtype - mutant) 
v-'targev 
Relative Expression = 
ST; \ ACt reference (wildtype - mutant) 
v^-reference/ 
In this equation, target represents the gene of interest (IE2) and reference represents the 
internal reference gene or calibrator (G6PD). 
Viral DNA replication assays 
To determine the effects of mutation in IE2 on viral DNA replication, BAC-
transfected cells were harvested at various time points using Trizol reagent (Invitrogen) 
according to the manufacturer's instructions. Real time PCR analysis was performed as 
described above using equal amounts of total DNA (100 ng). The primer sequence used 
for amplification of gB has been previously described (105). 
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Virus replication assays 
To determine the effects of mutations in IE2 on HCMV replication, supernatant 
from BAC-transfected cells was harvested at various time points and stored in -80°C. 
Virus replication assays were performed as described in Lorz, et al (77). Briefly, 20 ul of 
viral supernatant was incubated with 160 ul of 10 mg/ml proteinase K for 1 hour at 56°C. 
DNA was denatured by incubation at 95°C for 5 minutes. Viral DNA levels in the 
supernatant was assessed by real time PCR analysis as described previously using 10 ul 
of the extract as a DNA template and primers for gB DNA as described in Petrik, et al. 
(105). 
Results 
Generation of HCMV Towne BACs mutated in the IE2 gene 
Based on the results of our mutational analyses of IE2 in transient transfections, 
we speculated that mutations at amino acid 535 and 544 would demonstrate impaired 
transcriptional regulation in the context of the viral genome. We chose to continue 
evaluation of these mutants to test our hypothesis that they would be lethal to virus 
replication and to more closely investigate the transcriptional regulatory properties of IE2 
that are essential for activation of early genes. It is important to note that although IE2 
mutagenesis of the BAC construct resulted in an Alanine residue, consistent with in vitro 
studies, additional basepairs were mutated at amino acid 535 and 544 to ensure mutated 
IE2 did not revert back to wildtype during infection (see Materials and Methods) (149). 
Mutagenesis of the HCMV Towne BAC DNA was used to evaluate the effects of 
mutations in IE2 on replication and transcriptional regulation in the context of the viral 
67 
genome. The HCMV Towne BAC clone was kindly provided by Dr. Hua Zhu 
(University of Medicine and Dentistry of New Jersey, Newark, NJ) (86). This BAC 
construct replaces the US1 to US 12 region of HCMV, which is dispensible for infection, 
with a F-plasmid sequence (86). The F-plasmid sequence contains a GFP expression 
cassette, a chloramphenicol resistance marker, and an origin of replication for 
amplification in DY380 E. coli (86). DY380 cells were generated by modification of 
DH10B to express phage derived recombination genes under the control of a 
temperature-sensitive repressor, cl, and were kindly provided by Dr. Hua Zhu (71). 
Alterations in the endogenous IE2 gene of HCMV BACs was accomplished using 
a two step PCR approach (Fig. 14). In the first PCR reaction, the kanamycin resistance 
marker was PCR amplified from pGEM-oriV/kan-1 (kindly provided by Hua Zhu) using 
primers containing sequence homology to the kanamycin gene and a 20 bp overhang with 
homology to the C-terminus of IE2 between amino acids 449 and 579 (Fig. 14). This 
PCR fragment was gel-purified and transformed into electro- and recombination-
competent DY380 cells containing the wildtype HCMV Towne-BAC. Recombination of 
IE2 overhangs with the IE2 region resulted in deletion of amino acids 449 to 579 of IE2 
to generate the HCMV AExon5 BAC (Fig. 14). Positive clones containing successful 
deletion of the amino acids 449 to 579 and replacement of this region with the kanamycin 
resistance marker were confirmed by growth on LB agar plates containing kanamycin 
and chloramphenicol, PCR analysis and restriction enzyme digestion. 
Following generation and confirmation of the HCMV AExon5 BAC, the plasmid 
pIE2-Zeo-TOPO (containing Exon 5 of IE2 located upstream of Zeocin) was mutated by 
site-directed PCR at amino acid P535A or Y544A and used to generate HCMV mutant 
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BACs (Fig. 14A). In the second PCR reaction, the IE2 region between amino acid 449 
and 579 and the zeocin resistance marker flanked by loxP sites was amplified from 
wildtype or mutated pIE2-Zeo-TOPO (Fig. 14B). This was achieved using primers 
recognizing the pIE2-Zeo-TOPO fragment and containing IE2 overhangs with sequence 
homology to the HCMV IE2 region flanking amino acid 544 to 579. Amplification of 
wildtype pIE2-Zeo-TOPO plasmid containing the endogenous IE2 sequence was used to 
generate a wildtype- revertent (WT-Rev) BAC. Generation of a WT-Rev BAC is 
important to make sure that any additional DNA introduced in the generation of the 
HCMV BAC DNA during mutagenesis does not interfere with the IE2 phenotype. The 
PCR fragment was gel purified and transformed into DY380 cells containing the HCMV 
AExon5 BAC to generate recombinant BAC DNA. Positive clones were confirmed by 
growth on LB agar plates containing zeocin and chloramphenicol. In addition, BAC 
DNA was further of confirmed by PCR analysis, southern blot analysis and restriction 
enzyme digestion (Fig. 15 and 16). Comparison of the EcoRI/Salll restriction digestion 
pattern demonstrated introduction of the zeocin gene and confirms large scale 
rearrangements did not occur during the recombination procedure (Fig. 15 and 16). 
Wildtype (WT) and WT-Rev virus display similar growth and viral DNA replication 
kinetics 
During the generation of HCMV recombinant BAC DNA, we introduce DNA 
sequences not present into the original construct. Specifically, a BamHI restriction 
enzyme site and single loxP remain in the DNA following the IE2 stop codon when 
transfected in the presence of Cre Recombinase. To ensure that these sites do not 
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Amino acids 449-580 (Deleted in AExon 5 
g | p | BAC and expanded in mutated BACs to 
include zeocin qene) 
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WT AExon5 Rev P535A Y544A 
FIG. 15. Confirmation of Mutant HCMV BACs by PCR and restriction enzyme 
analysis. To confirm generation of mutant HCMV BACs the HCMV BAC screening 
primers (A) were generated to flank amino acid 449 to 579 of IE2 and used to PCR 
amplify the IE2 gene region. The gel fragments were separated on a 1.2% agarose gel. 
HCMV WT BAC results in a approximately 0.6 kb fragment using the indicated primers 
(arrows). With the introduction of the Zeocin, we see an increase in the size of this 
fragment to 1.1 kb in the WT-Rev, P535A and Y544A BAC constructs. With deletion of 
the IE2 C-terminus, we see no PCR product. (B) For restriction enzyme analysis, HCMV 
BACs were digested with Sail and Hindlll to confirm large scale rearrangements did not 
occur with mutations in HCMV BACs. Following digestion, fragmented DNA was run 
on a 0.8% agarose gel. 
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^ Q W I Smal 
2.77 kb 
1.68 kb 
FIG. 16. Confirmation of Mutant HCMV BACs by Southern Blot Analysis. To 
confirm generation of mutant HCMV BACs, HCMV BACs were digested with Smal 
restriction enzyme and separated by electrophoresis on a 1% agarose gel. DNA was 
transferred to a nylon membrane and probed by southern blot analysis as described in the 
Materials and Methods. As shown in the diagram above, genomic IE2 contains a two 
Smal recognition sites resulting in a 2.77 kb fragment (WT BAC). The cloning of the 
zeocin gene at the C-terminus of IE2 introduces an additional Smal recognition site, 
resulting in a 1.68 kb fragment as seen with WT-Rev, P535A and Y544A BACs. The 
arrows shown this diagram, indicate the primers used for southern probe generation 
which bind at amino acid 449 and 579 of IE2. 
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interfere with viral growth, we compared virus replication and viral DNA synthesis of the 
WT and WT-Rev BACs. WT and WT-Rev BAC DNA was transfected into primary 
fibroblasts and virus titers were determined for reconstituted virus. Primary fibroblasts 
were infected with 0.5 pfu/cell of virus and harvested daily for DNA. Virus supernatant 
was harvested and digested with proteinase K to determine levels of infectious virus in 
the supernatant. As shown in Fig. 17, wildtype and revertant viruses had similar levels of 
gB DNA in the supernatant confirming there was no difference in virus replication 
between WT and WT-Rev virus. To assess differences in viral DNA replication, 
genomic DNA was harvested from cells and assessed for gB DNA levels by real time 
PCR. Similar levels of IE2 gB DNA were found in the cells of WT and WT-Rev virus 
(Fig. 18). These results demonstrate that the additional sequences found in the WT-Rev 
virus, as well as the recombinant viruses with mutations in the IE2 gene, do not affect 
replication of HCMV. 
WT-Rev and mutant BAC DNA have similar transfection efficiencies 
We have demonstrated in the previous section that the WT and WT-Rev virus 
have similar replicative capacities during infection. Thus, further studies compared 
mutant phenotypes to that of the WT-Rev BAC. To ensure that there were no differences 
in transfection efficiency between WT-Rev and mutant BACs, BAC DNA was 
transfected into primary fibroblasts with Cre Recombinase and harvested at 1 day after 
transfection for genomic DNA. DNA levels were assessed by real time PCR as 
previously described. As shown in Fig. 19, we saw no noticeable differences in DNA 
levels at 1 day after transfection indicating the BAC transfection efficiency between WT-
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FIG. 17. Growth Curve Kinetics of HCMV WT and WT-Rev virus. WT-Rev and 
mutant HCMV BACs were transfected into primary fibroblasts by calcium phosphate 
transfections. Virus supernatants were harvested for genomic DNA at indicates times, 
following transfection and assessed for gB DNA levels by real time PCR. 
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FIG. 18. Replication of HCMV WT and WT-Rev viral DNA in primary fibroblasts. 
WT-Rev and mutant HCMV BACs were transfected into primary fibroblasts by calcium 
phosphate transfections. Genomic DNA was harvested from primary fibroblasts at the 
indicated times following transfection and assessed for gB DNA levels by real time PCR. 
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Transfection Efficiency of Recombinant BACs 
I EE REV 
FIG. 19. gB DNA levels at 1 day post transfection as an indicator of transfection 
efficiency. WT-Rev and mutant HCMV BACs were transfected into primary fibroblasts 
by calcium phosphate transfections. Cells were harvested for genomic DNA at one day 
following infection and assessed for gB DNA levels by real time PCR. DNA levels are 
expressed as mean ± SD within a representative experiment. 
Rev and mutant BACs. 
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Mutations in amino acid 535 and 544 inhibit virus replication 
The experiments performed in transient transfections suggest that mutations at 
535 and 544 inhibit activation of the UL54 and UL112-113 promoters. Since both of 
these proteins are essential for virus replication, we predicted that generation of these 
mutations in the HCMV BAC would not yield viable virus. Wildtype, WT-Rev, and 
mutant BACs were transfected into primary fibroblasts along with pp71 and Cre 
recombinase expression plasmids to investigate the effects of these mutations on virus 
replication. Recombinant BACs mutated at amino acid 535 and 544 were unable to 
generate viable virus when compared to WT or WT-Rev virus (data not shown). Plaques 
appeared after approximately 6 days in cells transfected with WT and WT-Rev BACs. 
Cells transfected with the IE2 mutated BACs were monitored and maintained for up to 6 
weeks following several repetitions with no indication of virus replication. These results 
confirm that mutations in IE2 prevent the generations of viable virus when compared to 
WT or WT-Rev virus. 
Mutations in IE2 reduce activation of early gene promoters 
One possible reason for the lack of viable HCMV infectious virus production is 
an inability to efficiently replicate viral DNA. To determine the stage in which virus 
replication may be blocked, viral RNA of BAC transfected cells were assessed by real 
time PCR. Total RNA was isolated from cells harvested at various days post transfection 
and reverse transcribed into cDNA. UL54 and UL112-113 mRNA transcript levels were 
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then measured by real time PCR. Unlike our results in vitro, we observed differences in 
regulation of UL54 and UL112-113 promoters between recombinant viruses containing 
mutations in IE2 at amino acid 535 and 544 (Fig. 20). It is important to note that since 
virus replication began at 6-7 days post transfection, that promoter regulation at 1 and 4 
days post transfection represent transcriptional activation or repression. RNA levels at 7 
and 10 days post transfection most likely represent differences in virus replication. 
In fibroblasts transfected with the WT-Rev HCMV BAC, we observed a 6-fold 
increase in UL54 transcript levels 4 days following transfection (Fig. 20). Since we do 
not begin to see high levels of viral particles in the cell until 4-5 days after transfection, 
this most likely represents an increase in UL54 activation. We continue to see a rise in 
UL54 transcript levels at 7 days post transfection, indicative of virus replication and 
spread to adjacent cells (Fig. 20). 
Interestingly, the mutation in IE2 at amino acid 535 displays wildtype-Rev levels 
of UL54 activation at 1 and 4 days following transfection suggesting an ability to activate 
the UL54 promoter (Fig. 20). However, at 7 days post transfection the UL54 activation 
levels reduced significantly (Fig. 20). In contrast, cells transfected with recombinant 
BAC DNA mutated at amino acid 544 display significantly lower levels of UL54 
transcripts at all days post transfection suggesting an inefficiency to activate the UL54 
promoter at all time-points tested (Fig. 20). The ability of the IE2 protein mutated at 
amino acid 535 to efficiently regulate UL54 activation, suggests that the mutation at 544 
may disrupt a property of IE2 required for UL54 activation which is maintained with a 
mutation at 535. Similar to transient transfections, IE2 protein with mutations in amino 
acids 535 and 544 were unable to activate the UL112-113 promoter 
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FIG. 20. Regulation of the UL54 promoter in BAC transfected cells. Total RNAs were 
isolated from BAC transfected cells as described in Materials and Methods and analyzed 
by quantitative real-time RT-PCR with using primers specific for UL54 cDNA. 
Experiments were performed in duplicate with 2 independent experiments and mRNA 
expression levels were expressed as mean ± SD. An asterisk (*) indicates statistically 
significant difference (P<0.05), wildtype-Rev versus mutant IE2. 
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after day 1 as shown in Fig. 21. The failure of both mutant IE2 proteins to activate the 
UL112-113 promoter suggests both mutations disrupt a functional property of IE2 
required for UL112-113 activation. 
Mutations in IE2 prevent repression of MIE promoter early in infection. 
The IE2 protein has been shown to autorepress the MIE promoter (20, 48, 69, 74, 
83, 107). To determine the effects of mutations in IE2 at amino acid 535 and 544 on 
MIE autorepression in BAC transfected cell, we evaluated MIE mRNA expression at 
various times after transfection, as previously described. Following transfection of 
wildtype reverent BAC, mRNA expression levels of IE2 remain stable at 1 and 4 days 
post transfection, then begin to increase at 7 and 10 days post infection due to virus 
spread (Fig. 22). Similar to results observed in transient transfections (Fig. 10), 1 day 
following transfections of BAC DNA, mutations in IE2 at amino acid 535 and 544 were 
unable to repress the MIE promoter resulting in a 65- and 4-fold increase in IE2 mRNA 
levels, respectively (Fig. 22). These results confirm our transient assays demonstrating 
that mutations in IE2 result in loss of MIE autorepression and UL54 activation. 
Discussion 
Herpesviruses are significant pathogens for animal and humans, emphasizing the 
need for characterization of viral genes that regulate replication. Analysis of functional 
properties both in vitro and in vivo is essential for understanding the distinct function of 
individual gene products. The most common strategy used to evaluate the function of a 
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FIG. 21. Regulation of the UL112-113 promoter in BAC transfected cells. Total 
RNAs were isolated from BAC transfected cells as described in Materials and Methods 
and analyzed by quantitative real-time RT-PCR with using primers specific for UL112-
113 cDNA. Experiments were performed in duplicate with 2 independent experiments 
and mRNA expression levels were expressed as mean ± SD. An asterisk (*) indicates 
statistically significant difference (PO.05), wildtype-Rev versus mutant IE2. 
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FIG. 22. Regulation of the MIE promoter in BAC transfected cells. Total RNAs were 
isolated from BAC transfected cells as described in Materials and Methods and analyzed 
by quantitative real-time RT-PCR with using primers specific for UL54 cDNA. 
Experiments were performed in duplicate with 2 independent experiments and mRNA 
expression levels were expressed as mean ± SD. An asterisk (*) indicates statistically 
significant difference (P<0.05), wildtype-Rev versus mutant IE2. 
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viral protein in the context of a viral infection is to generate mutations within the gene 
and determine the effects of those mutations on the phenotype of the mutated virus. Due 
to the critical role of IE2 in HCMV infection, it is difficult to generate recombinant 
viruses containing mutations in IE2. To circumvent this problem, we utilized HCMV 
Towne BAC constructs. These constructs allow mutagenesis of the viral genome and 
expression in human fibroblasts. 
Our transient data suggests that mutations in the C-terminus of IE2 result in loss 
of IE2 transcriptional regulation of immediate early and early viral promoters. However, 
excluding the MIE gene products, these experiments are performed in the absence of 
other HCMV gene products which may influence promoter regulation in the presence of 
mutant or wildtype IE2 protein. The use of HCMV BACs will allow us to assess viral 
gene regulation in the context of the HCMV genome. 
Generation of HCMV BACs mutated in the IE2 gene 
To determine the effects of mutations in IE2 on transcriptional regulation and 
virus infection, we mutated HCMV recombinant BAC DNA. The generation of single 
amino acid substitutions in IE2 required a complex process of BAC mutagenesis by 
homologous recombination and confirmation of BAC DNA fidelity by PCR 
amplification, southern blot analysis and restriction enzyme digestion. These methods of 
confirmation were important to ensure that mutagenesis of the IE2 protein did not result 
in aberrant mutations within the HCMV genome. Based on these methods, we were able 
to successfully confirm the generation of mutations in IE2 at amino acids P535A and 
Y544A. 
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HCMV Wildtype and WT-Rev BACs have a Similar Phenotype 
To ensure any sequence DNA introduced into the HCMV BAC DNA during BAC 
generation did not influence functions and/or properties of IE2, a wildtype-revertent BAC 
(WT-Rev) was generated, as previously described. Similar to WT BAC DNA, the 
revertant was able to successfully replicate in fibroblasts and produce infectious particles. 
To ensure there were no significant differences in viral DNA replication, we isolated 
DNA from WT or WT-Rev infected cells and analyzed for gB levels by real time PCR. 
A similar methodology was used to evaluate virus replication by analysis of gB levels in 
the supernatant at indicated times post infection. As shown in Fig. 17 and 18, we 
observed no noticeable differences in virus replication or DNA replication between WT 
and WT-Rev virus. These results confirm that the WT-Rev BAC behaves similar to WT 
and allowed us to continue experiments using WT-Rev BAC as a control. 
Mutations in IE2 Inhibit Virus Replication 
HCMV recombinant viruses were transfected into primary fibroblasts and 
monitored for plaque formation as an indicator of virus replication. BAC constructs 
containing mutations in IE2 were unable to form plaques even after 6 weeks compared to 
WT or WT-Rev virus where plaques became visible after approximately 6 days (data not 
shown). Levels of viral DNA were assessed at 1 day after transfection to ensure all 
recombinant BACs had similar transfection efficiency (Fig. 19). Real time PCR analysis 
demonstrated that there were no significant differences in transfection efficiency between 
wildtype revertant and mutant BACs. Thus, we can conclude that mutations in IE2 at 
amino acid 535 and 544 prevent efficient HCMV replication. 
85 
UL112-113 Early Gene Activation is Impaired with mutations in IE2 within HCMV 
BACs 
With the absence of infectious viral particles from recombinant viruses with 
mutation in IE2, we next sought to determine the effects of these mutations on 
transcriptional regulation of early promoters. Our studies in transient assays suggested 
that the mutations generated in IE2 would prevent IE2-mediated transactivation of early 
gene promoters. To evaluate promoter activation, we isolated RNA at various times after 
BAC transfection, synthesized cDNA using random hexamers, and performed real time 
PCR analysis. When compared to wildtype revertant at all time points, minimal to no 
UL112-113 mRNA was detected with mutations in IE2 at both amino acid 535 and 544. 
The UL112-113 locus encodes four phosphoproteins early and late in infection 
which are required for virus replication and serve as transactivators of the UL54 promoter 
(53). Studies show that the UL112-113 promoter is controlled by an essential 
ATF/CREB and a nonessential IE2 binding site (113). The ATF/CREB binding is 
required for activation early in infection (8 to 24 hours), whereas IE2 binding has only a 
moderate transactivation function (113), Late in infection (72 hours), ATF/CREB 
binding becomes less important and the mechanism of transcriptional regulation is 
unclear (113). Previous studies demonstrate that IE2 can interact with ATF/CREB 
family members (80). Since IE2 is unable to activate UL112-113 early in infection, it is 
possible that IE2 is required for recruitment of ATF/CREB to the UL112-113 promoter 
and that our mutations in IE2 disrupt this interaction. Future studies will assess mutated 
IE2 for its ability to bind ATF/CREB family members. Since UL112-113 is essential for 
replication (102), it is likely that loss of UL112-113 activation is a significant reason for 
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loss of virus replication for recombinant HCMV BACs. 
Regulation of UL54 Early Gene Activation by mutated in IE2 within HCMV BACs 
The UL54 promoter is regulated by a number of viral and cellular transcription 
factors (59, 61, 62, 81). Transient transfections demonstrate that mutations in IE2 at both 
amino acid 535 and 544 prevent UL54 activation (Fig. 8). Consistent with our in vitro 
analysis, mutagenesis of IE2 at amino acid 544 results in a significant reduction in UL54 
promoter activation. However, in the context of the viral genome it appears that the 
mutation in IE2 at 535 does not impair UL54 activation. This discrepancy may be due to 
the presence of additional HCMV viral gene products which may be able to compensate 
for a functional defect in IE2 generated by a mutation at amino acid 535. In addition, it is 
possible that the mutation at amino acid 535 may disrupt a property of IE2 not essential 
for activation of UL54 during virus infection. 
Previous studies suggest the UL54 promoter is primarily regulated by a SP1 
binding site at early times in infection and an ATF-1 binding late in infection (59, 61, 62, 
81). The IE2 protein is hypothesized to form a bridge between TBP and SP1 to stabilize 
the complex at the UL54 promoter. IE2 is also thought to interact with ATF-1 at the 
promoter to enhance transcription (61). In addition, IE2 interacts with HDAC2, a cellular 
repressor of the UL54 promoter, during virus infection to prevent UL54 repression (14). 
Due to the numerous roles IE2 may play in regulating the UL54 promoter, it is unclear 
which property may be leading to the phenotype demonstrated by the mutation at amino 
acid 544. Chapter 5 will begin addressing this question using transient assays. 
In addition to direct effects of IE2 on UL54 activation, it is also important to note 
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that the UL112-113 gene products function to enhance UL54 activation in the presence of 
MIE gene products in transient assays. Thus, a decrease in UL54 activation may be 
partially due to loss of UL112-113 promoter activation, described in the previous section. 
However, activation of UL54 in the presence of a mutation in IE2 at amino acid 535, still 
occurs in the absence of UL112-113 activation. This suggests that expression of the 
UL112-113 gene products may not be required for activation of the UL54 promoter. In 
future studies, it will be important to investigate expression of other viral proteins, such 
as the IRS 1/TRS1 gene products. 
Mutations is IE2 Disrupt Autorepression of the MIE promoter at Early Times in 
Infection 
IE2 is able to autorepress it own promoter, the MIE promoter. Consistent with 
transient studies, we observe differences in MIE promoter regulation with mutations in 
IE2 at 535 and 544. At 1 day following BAC transfections, the level of IE2 RNA present 
in the cell is 50 and 60-fold higher than wildtype for P535A and Y544A, respectively. 
However, these levels decrease to wildtype levels by 4 days and remain low at 7 and 10 
days after transfection indicative of loss of virus replication. These results indicate that 
mutations in this region of IE2 alleviate repression of the MIE promoter early in 
infection. Since the MIE promoter is primarily down-regulated by binding of IE2 to the 
promoter, it will be interesting to see if IE2 binding is disrupted by mutations in IE2. 
Since IE2 activates a number of viral and cellular promoters, it is not surprising 
that increased expression of the MIE gene products would lead to impaired 
transcriptional regulation and replication. Although the mechanism of impairment is 
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unclear, increased expression may lead to a dominant negative phenotype or sequester 
other factors important in transcriptional regulation. It is also possible that although 
levels of IE2 mRNA increase with mutations in IE2, protein expression levels may not. 
Evaluation of IE2 protein expression will be addressed in future studies. Lastly, even in 
the situation of increased IE2 protein levels, it is likely that mutated IE2 is nonfunctional 
and unable to activate essential genes, as demonstrated in UL54 and/or UL112-113 
regulation. 
A recent study evaluated the effects of a double mutation in the HCMV BAC at 
amino acid 535 and 537 (105). Although the study described in this dissertation utilized 
HCMV BACs containing single amino acids, it is possible that the mutation at P535A 
would display a phenotype similar to the A535/537 mutation. Consistent with our 
findings for the mutation at amino acid 544, the study evaluating A535/Y537 
demonstrated that this mutated BAC was unable to activate transcriptional regulation of 
the UL112-113 and UL4 early genes. However, our mutation at 535 retained UL54 
activation early in infection (Fig. 20). Since the double mutation at 535/537 and our 
mutation at amino acid 544 both disrupt Tyrosine residues, it may be possible that these 
amino acids have a functional role of IE2-mediated transcriptional regulation facilitated 
by biochemical properties or posttranslational modification of Tyrosine residues. 
Contrary to our findings, previous reports indicate that mutations at the 
P535/Y537A residues in HCMV BACs autorepress the MIE promoter similar to 
wildtype. In our study, both the mutations at amino acid 535 and 544 resulted in a 
significant increase of IE2 mRNA one day after transfection, suggesting a loss of 
autorepression. One possible explanation for this discrepancy is a difference in the time 
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at which RNA expression was assessed between the two studies. Isolation of P535/537A 
RNA occurred at 48 hour following transfection and mutants in this study were isolated 
at 1 day post infection. However, due to the significant level of IE2 RNA present at 1 
day following transfection (68.5-fold increase), it is unlikely that levels could be reduced 
to this extent after only one day. A more likely explanation for this difference is the type 
of mutations made in the recombinant BAC. For example, the Tyrosine 537 mutation 
may partially compensate for the Proline 535 mutation with respect to autorepression. 
Summary 
The use of recombinant HCMV BACs have provided a more biologically relevant 
analysis of functional properties of IE2 that may be important for transcriptional 
regulation. These studies support the hypothesis that IE2 regulates different early viral 
promoters by both independent and overlapping mechanisms. For example, a mutation in 
IE2 amino 544 can disrupt autoregulatory, and UL54 and UL112-113 transactivation 
functions of IE2, but a mutations at 535 disrupts only IE2 autoregulation and UL112-113 
transactivation. To elucidate functional properties of IE2 required for transcriptional 
regulation of individual promoters, comprehensive functional assays, evaluating IE2 
interactions with cellular and viral proteins, and interactions with DNA will be required 
both in vitro and in the context of a virus infection. 
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CHAPTER V 
IE2 RECRUITMENT TO THE UL54 PROMOTER AND INTERACTIONS WITH TBP 
ARE IMPORTANT FOR UL54 ACTIVATION 
Introduction 
The UL54 promoter is thought to be regulated by both viral and cellular 
transcription factors (59, 61, 62, 81). The IE2 protein regulates transcription through the 
following potential mechanism(s): binding directly to the promoter region, interactions 
with cellular factors at the promoter, or working in cooperation with other viral promoters 
such as IE1. At the UL54 promoter, studies have shown that IE2 is able to sequester 
cellular repressors, such as HDAC2 to prevent UL54 repression (98). In vitro studies 
also suggest that IE2 interacts with the both the SP1 and TBP cellular factors to enhance 
UL54 activation in transient assays (59, 62). Last, studies suggest IE2 may bridge SP1 
and TBP at the UL54 promoter, stabilizing the complex and thereby enhancing 
transcription (59, 62). Many studies using mutagenesis to map functional domains of IE2 
have neglected to investigate the functional properties of IE2 disrupted by mutagenesis in 
IE2. 
In this dissertation, we have investigated the effects of mutations in IE2 on 
transcriptional regulation of viral genes in transient assays and in the context of the viral 
genome. Mutations in IE2 at amino acid 535 and 544 prevented activation of the UL54 
and UL112-113 promoters in transient assays. In the context of the viral genome, the 
mutation at amino acid 544 inhibited activation of the UL54 and UL112-113 promoters, 
consistent with in vitro studies. In contrast, cells transfected with BACs containing a 
mutation at 535 did not activate UL112-113, but expressed similar levels of UL54 
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mRNA. In addition, both mutations resulted in a loss of autorepression of the MIE 
promoter in transient assays and in the context of a virus infection. 
There are several potential methods used to assess functional properties of IE2 
that may be disrupted by mutations. IE2 is able to regulate UL54 activation by 
interactions with cellular proteins and recruitment to the viral promoter. Co-
immunoprecipitations (ChIP) assays and GST pulldowns are commonly used to assess 
protein-protein interactions. Gel shift assays are commonly used to evaluate the ability of 
proteins to bind DNA. However, gel shifts are only able to detect direct DNA binding. 
Chromatin immunoprecipitations can be used to evaluate recruitment of proteins to a 
promoter of interest and thereby assess direct and indirect protein-DNA interaction. 
To investigate properties of IE2 important in transcriptional regulation the UL54 
promoter, we investigated IE2 functional properties of the mutated proteins using the 
following two approaches. First, GST pulldown assays were used to evaluate IE2-protein 
interactions in the presence of IE2 mutations. Second, ChIP assays were performed to 
determine whether the mutated IE2 protein is able to be recruited to the UL54 promoter. 
These experiments are significant in defining functional properties of IE2 that may be 
required for transcriptional regulation. 
Materials and Methods 
Mammalian Cells 
HeLa cells were obtained from ATCC and grown in Iscove's Medium with 10% 
fetal bovine serum (FBS, Invitrogen), 100 IU/mL penicillin and 100 ug/mL streptomycin 
(Sigma). HeLa cells were split at a ratio of 1:5 at 90% confluency. 
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Plasmids Used for Evaluation of IE2 Functional Properties 
GST Expression Plasmids 
To assess IE2 protein interaction with cellular transcription factors in vitro, GST 
fusion proteins were generated. For generation of a plasmid expressing TBP protein 
fused to a GST tag, the TBP sequence was PCR-amplified from primary human fibroblast 
cDNA using primers as described in Inada, et al (50). The sequence was TA subcloned 
into the pSC-A vector according to manufacturer's directions (Stratagene), and then 
cloned into pGEX-6P-l using EcoRI digestion to generate pGEX-TBP. Plasmids were 
confirmed by sequencing using 3' pGEX and 5' pGEX sequencing primers (Amersham). 
In Vitro Transcription/Translation Plasmids 
The plasmid pBS-IE2 was received as a gift from Jay Nelson and used to express 
IE2 for in vitro transcription/translation assays. For correction of aberrant mutations in 
IE2, the SmaI-Bsu36I fragment from pSVHk was extracted and transferred into pBS-IE2 
(as described in (5)). 
Real Time PCR Plasmids 
G6PD-TOPO plasmids were generated by PCR amplification and TOPO cloning 
as previously described. Similarly, pUL54-CAT-TOPO plasmids were generated as 
previously by PCR amplification of pUL54-CAT using the following forward and reverse 
primers amplifying the promoter region of pUL54-CAT: 5'-GCC GCT GCA GAA CCT 
CTT TC -3' and 5'-CCT TAG CTC CTG AAA ATC TCC C-3', respectively. 
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Molecular Cloning and Generation of Plasmid DNA 
Molecular cloning techniques and generation of plasmid DNA were performed as 
previously described in Chapter 3. 
GST Pulldown Assays 
In vitro transcription/translations (IVTT) 
Generation of recombinant IE2 and mutant IE2 proteins in vitro were performed 
using the TnT Coupled Reticulocyte Lysate System (Promega) with 30 uCi (Specific 
Activity >1000Ci/mM) of 35S-methionine (Amersham) according to manufacturer's 
directions using T7 RNA polymerase. Expression of the translated proteins and input 
quantification was tested using 5% of total reaction and was resolved on a 10-20% 
Gradient Tris-HCL Ready Gel (Bio-Rad) after boiling proteins for 5 minutes in the 
presence of IX SDS-PAGE Loading Dye (5% glycerol, 1% SDS, 80 mM Tris-HCl, pH 
6.8, Bromophenol blue) and 2 ul of J3-mercaptoethanol . After electrophoresis the gel 
was dried at 85°C for 1 hour and exposed to phosphor screen. The image was visualized 
using a Typhoon 9410 Variable Mode Imager. Protein quantification was performed 
using ImageQuant TL Software. The use of radioactive materials in this dissertation was 
approved by the Eastern Virginia Medical School Radiation Safety Committee. 
Propagation and Purification of GST and GST Fusion Proteins. 
Overnight cultures of E. coli BL21 containing one of the GST fusion constructs 
were diluted 1:20 in LB with ampicillin and grown to an OD6oo=0.6. IPTG was added to 
a final concentration of 0.1 mM then incubated at 30°C for 3 hours with shaking. 
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Bacteria were pelleted and resuspended in 25 mis of Buffer A (20 raM HEPES, pH 7.2, 
100 mM KC1, 0.2 mM EDTA, 20% Glycerol, 1% Triton X-100). Bacteria were 
sonicated four times for 30 seconds on ice at 10 Watts using a Fisher Scientific Sonic 
Dismembrator Model 100 (1/8 inch tip), then centrifuged at 19,800 X g for 10 minutes. 
GST fusion proteins were precipitated using Glutathione sepharose (GE 
Healthcare) according to manufacturer's instructions. Briefly, 400 ul of Glutathione 
Sepharose was incubated with purified GST protein for 2 hours at 4°C (with rotation). 
The GST protein complexed to glutathione sepharose was washed five times in NETN 
Buffer (0.5% NP-40, 20 mM Tris, pH 8.0, 100 mM sodium chloride, 1 mM EDTA) 
following centrifugation for 5 minutes at 500 X g. The pellet was resuspended in 150 ul 
of NETN and an aliquot was resolved on a 10-20% Gradient Tris-HCL Ready Gel (Bio-
Rad) by brief centrifugation, following by boiling for 5 minutes in the presence of SDS-
PAGE Loading Dye and 2 ul of B-mercaptoethanol. The gel was stained overnight in 
SYPRO Ruby Protein Gel Stain (Invitrogen) diluted 1:1 in water. The following day, the 
gel was visualized on the Kodak Gel Logic 200 Imaging System. Protein quantification 
was performed using ImageQuant TL Software. 
GST Pulldown Assays. 
GST protein was first equilibrated with 500 ul Binding Buffer (25 mM HEPES, 
pH 7.5, 12.5 mM magnesium chloride, 20% glycerol, 0.1% NP-40, 150 mM potassium 
chloride, 0.15mg/ml bovine serum albumin, 1 mM DTT) and spun at 500 X g for 5 
minutes at 4°C. The GST pellet was then resuspended in 200 ul fresh binding buffer. 
GST pulldowns were performed by incubation of the purified GST fusion 
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protein/Glutathione Sepharose complexes with 20 ul of radiolabeled protein for 2 hours 
at 4°C (with rotation). Following incubations, complexes were purified by centrifugation 
at 500 X g at 4°C for 5 minutes. Complexes were washed 5 additional times in 1 ml of 
NETN and spun at 500 X g at 4°C for 5 minutes. Protein complexes were denatured by 
boiling and resolved by SDS-PAGE on 12.5% acrylamide gels. After electrophoresis the 
gel was dried at 85°C for 1 hour and exposed to a phosphor screen. Image was visualized 
using a Typhoon 9410 Variable Mode Imager. Protein quantification was performed 
using ImageQuant TL Software. 
Transfection of HeLa Cells for Chromatin Immunoprecipitations 
HeLa cells (1.5 X 106 cells per 150 mm dish) were transfected by the calcium 
phosphate technique (41). Briefly, each plate was transfected with 80 ug of total DNA. 
For each sample, 50 ul of 2.5M Calcium Chloride (CaCb) was added to a 6 ml tube, 
followed by 1500 ul of 2X HBS (280 mM NaCl, 10 mM KC1, 1.5 mM Na2HP04, 12 mM 
dextrose, 50 mM HEPES, pH 7.5). This reaction was incubated 30 minutes at room 
temperature then added to cells dropwise. Media was changed 20 hour after transfection 
and cells were harvested for chromatin immunoprecipitations (ChIP) assays 24 hours 
after the media was changed. 
Chromatin Immunoprecipitations (ChIP) 
Harvesting cells and Crosslinkingfor ChlPs 
In order to assess the effects of mutations in IE2 on recruitment of IE2 or RNA 
polymerse II to the UL54 promoter, HeLa cells were transfected with IE2 expression 
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constructs in the pMCRS86 vector and pUL54-CAT by calcium phosphate transfections. 
Transfected cells were crosslinked with 1% formaldehyde for 10 min at 37°C. Media 
was removed and cells were washed twice in cold IX PBS containing Complete EDTA-
free protease inhibitors (Roche). Cells were scraped into a 2.0 ml eppendorf tube and 
centrifuged at 500 X g for 4 minutes. The cell pellet was resuspended in 800 ul of SDS 
Lysis Buffer (1% SDS, lOmM EDTA, 50mM Tris-HCl, pH 8.1) containing protease 
inhibitors and incubated on ice for 10 minutes. Cells were either sonicated immediately 
or stored at -80°C. 
Fragmentation of total DNA by sonication ofHeLa Cells 
To assess protein recruitment at individual promoters, DNA was fragmented by 
sonication to a size of 500-1000 basepairs. Using a Fisher Scientific Sonic Dismembrator 
Model 100 (1/8 inch tip), cells were sonicated on ice for 12 pulses at 30 seconds/pulse 
and 10 Watts. Cell lysates were centrifuge at a maximum speed for 10 minutes. The 
supernatant was diluted 10 fold in ChIP dilution buffer (0.01% SDS, 1.1% Triton X-100, 
1.2mM EDTA, 16.7mM Tris-HCl, pH 8.1, 167mM NaCl) containing protease inhibitors 
and used immediately or stored at -80°C. 
To confirm DNA fragment sizes following sonication, a 400 ul aliquot was 
incubated with 20 ul of 5M NaCl at 65°C overnight. The next day, DNA was purified 
using Qiagen's PCR purification kit according to the manufacturer's instructions and 
electrophoresed on a 1.2% agarose stained in ethidium bromide as previously described. 
97 
Immunoprecipitation of Protein-DNA Complexes 
Monoclonal antibodies against IE2 (MAB810) and RNA polymerase II (05-623, 
Millipore) were used to immunoprecipitate chromatin. To subtract background levels, 
mouse IgG2a and mouse IgG (Sigma) isotype matched controls, respectively, were 
included with each experiment. ChIP assays were performed by incubating a 400 ul 
aliquot of sonicated DNA in ChIP dilution buffer with 5 ug of the specified antibody or 
isotype matched control antibody overnight at 4°C (with rotation). An additional 400 ul 
of the sonicated DNA diluted in ChIP dilution buffer was stored at -80°C for 
quantification of the amount of input DNA present in each experiment. Following the 
overnight incubation, immunoprecipitation reactions were incubated with 60 ul of 
Salmon Sperm DNA/Protein A Agarose Slurry for one hour at 4°C with rotation. 
Agarose was pelleted by centrifugation at 500 X g at 4°C for 1 minute. The supernatant 
was removed and the agarose was washed by rotation for 5 minutes at 4°C with 1 ml of 
each of the following buffers in the order listed: 
A) Low Salt Buffer (0.1% SDS, l%Triton X-100, 2mM EDTA, 20mM Tris-HCl, 
pH 8.1, 150mM NaCl), one wash 
B) High Salt Buffer (0.1% SDS, l%Triton X-100, 2mM EDTA, 20mM Tris-
HCl, pH 8.1, 500mM NaCl), one wash 
C) LiCl Buffer (0.25M LiCl, 1 % NP40, 1 % deoxycholate, 1 mM EDTA, 
lOmM Tris-HCl, pH 8.1), one wash 
D) IX TE (lOmM Tris-HCl, ImM EDTA,pH 8.0), two washes 
Protein-DNA complexes were then eluted from agarose beads by the addition of 250 ul 
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of elution buffer (1%SDS, 0.1M NaHCOa), vortexed for 15 seconds then rotated for 15 
minutes at room temperature. The reaction was centrifuged for 1 minute at 500 X g and 
the eluate transferred to a new tube. The remaining agarose beads were washed once 
more in 250 ul of elution buffer and eluates were combined. To reverse crosslinks, 
protein-DNA complexes were incubated with 25 ul of 5M NaCl overnight at 65C. DNA 
was isolated as previously described. 
Real-Time PCR 
DNA levels were assayed by Real time PCR using iQ SYBR green supermix 
(Invitrogen) in a total of 25 ul, containing 12.5 JJ.1 of mastermix, 300 nM of specific 
primers, and 1-5 ul of cDNA. PCR Primers, pUL54-CAT forward and reverse (described 
in Real Time PCR Plasmids), were designed to detect the promoter region fragment in the 
ppol-CAT plasmid as described above. Real time PCR reactions were performed with a 
Biorad iCycler system using the standard curve method of quantification. Each PCR was 
performed as follows: initial uracil DNA glycosylase decontamination at 50°C for 2 min, 
a 2 min hot-start denaturation at 95°C, and 39 amplification cycles (15 s at 95°C, 30 s at 
58.7°C). Melting Curve analysis was performed to ensure the specificity of PCR product 
and lack of primer-dimer artifacts. The melting temperature of the final double-stranded 
DNA products was determined by gradual heating from 55°C to 95°C for 80 cycles with 
a 0.5°C increase after each cycle. 
Quantification of DNA and RNA by Real Time PCR 
Serial dilutions of the plasmid, pUL54-CAT-TOPO, from 109 to 103 copies were 
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used for determination of the PCR efficiency for each primer set. Each reaction was 
performed in duplicate and error bars reflect standard deviations within each experiment. 
Significance was determined by a P-value < 0.05 using a two-tailed Student's T-test. The 
ratio of target gene mRNA expression relative to the internal control was calculated as 
described in (106) using the following equation (where E is the efficiency of real time 
PCR amplification for the specified gene): 
/'T} \ACt target (wildtype - mutant) 
U-'target) 
Relative Expression — 
/-p \ ACt reference (wildtype - mutant) 
V-reference/ 
In this equation, target represents the promoter region of interest (UL54-CAT) and 
reference represents the internal reference gene or calibrator (Input). 
Results 
Mutations in IE2 inhibit in IE2 association with TBP in vitro 
IE2 is able to regulate viral gene expression by direct or indirect binding to the 
viral promoters or interactions with cellular and viral factors at the promoter (115). 
Previous studies suggest that IE2 may be recruited to the UL54 promoter due to 
interactions with cellular factors, such as TBP (59, 62). To determine if our mutations in 
the C-terminus of IE2 disrupt the interaction of IE2 with TBP, we performed GST 
pulldown assays. In order to synthesize radiolabeled wildtype and mutated IE2 protein 
we used the TnT Rabbit Reticulocyte Protein Labeling Kit (Promega) to perform in vitro 
transcription and translation. The IE2 wildtype and mutated plasmids containing the IE2 
cDNA under the control of the T7 bacteriophage promoter were used as DNA templates 
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for coupled in vitro transcription and translation in the presence of S-labeled 
methionine. Successful labeling and expression of IE2 wildtype or mutant protein was 
confirmed prior to GST pulldown assays (Fig. 23A). As a positive control, a luciferase 
plamid was in vitro transcribed and translated to generate a monomeric protein of 61 
kDa. A negative, mock control was also included in which no DNA template was added 
to the reaction. GST and GST-TBP proteins were generated by expression in BL21 
bacterial cells and purified using glutathione sepharose beads. GST proteins were 
separated on a 10-12.5% Gradient SDS-PAGE gel to confirm protein expression. As 
shown in Fig. 23B, we were able to successful generate GST and GST-labeled TBP 
proteins. Lower molecular weight proteins were expressed which are most likely GST-
TBP breakdown products. 
GST pulldown assays were performed by incubating the IE2 protein with equal 
concentrations of GST or GST-TBP protein and purification of protein complexes by 
glutathione sepharose beads (Fig. 24). Consistent with previous studies (17), our 
experiments show that wildtype IE2 protein is able to interact with TBP (Fig. 24). The 
IE2 mutated protein, Proline 535, also associates with TBP levels similar to wildtype 
(Fig. 24). In contrast, the mutation at Tyrosine 544 showed reduced binding with TBP, 
demonstrating a potential loss in IE2 interaction with TBP (Fig. 24). BACs containing 
IE2 with a mutation at amino acid 544 were unable to activate the UL54 promoter in 
BAC transfected cells, when compared to WT-Rev and recombinant BAC containing 
mutations amino 535, suggesting that interactions with TBP may facilitate this difference 
in regulation (Fig. 20). 
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FIG. 23. Generation of Protein for GST Pulldown Assays. (A) Wildtype and mutated 
35S labeled IE2 protein was generated by in vitro transcription/translation reactions. 
Protein expression of translated protein and input quantification was tested using 5% of 
the total reaction and was resolved on a 10-20% Gradient Tris-HCL Ready Gel. A 
positive and negative control were included. (B) GST fusion proteins were precipitated 
using Glutathione Sepharose (GE Healthcare) according to manufacturer's instructions. 
A 10% aliquot was resolved on a 10-20% Gradient Tris-HCL Ready Gel and stained 
overnight in SYPRO Ruby Protein Gel Stain before visualization on the Kodak Gel Logic 
200 Imaging System. 
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FIG. 24. Mutation in IE2 Inhibit Interactions with TBP. Wildtype and mutated 35S 
labeled IE2 protein was incubated with bacterially expressed GST or GST-TBP. GST 
complexes were purified by glutathione sepharose beads. Input amounts are shown on 
Fig. 23. Following extensive washings, immunoprecipitated proteins were eluted from 
beads, separated on a 12.5% SDS-PAGE and visualized on a Typhoon imager. 
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Mutations in IE2 prevent IE2 recruitment to the UL54 Promoter 
Studies have shown that IE2 expression is important for efficient activation of the 
UL54 promoter (59). IE2 has also been shown to interact with several transcription 
factors and members of the basal transcription machinery (43, 44, 57, 58). To date, 
studies have not looked at recruitment of IE2 to the UL54 promoter in transiently 
transfected cells. To determine if IE2 is present at the UL54 promoter and if mutations in 
IE2 alter recruitment to the promoter in transiently transfected cells, HeLa cells were 
transfected with the UL54-CAT plasmid and mutant IE2 cDNA expression vectors. 
HeLa cells were used for transfections instead of primary fibroblasts because they have 
an increased transfection efficiency than primary fibroblasts. Cells were cross-linked and 
harvested for ChIP assays. Following immunoprecipitations with the appropriate 
antibodies, cells were washed intensively, cross-links were reversed, and isolated DNA 
was assessed by real time PCR analysis. An isotype matched control antibody was 
included with each experiment. For each antibody tested, background levels of isotype 
matched control antibodies were below the level of detection by real time PCR (data not 
shown). 
For these experiments, we continued to assess the mutations at amino acids 535 
and 544 to determine if mutations in this region affect the transcriptional regulatory 
properties of IE2. ChIP assays with the IE2 antibody demonstrate that the mutation at 
amino 535 and 544 resulted in a significant loss of IE2 protein recruitment to the UL54 
promoter compared to the wildtype protein (Fig. 25). 
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Recruitment of IE2 to UL54 Promoter 
1.5n 
FIG. 25. Recruitment of Mutant IE2 Protein to the UL54 promoter. HeLa cells were 
transfected with 40 ug UL54-CAT plasmid and 40 |ag of parental or mutant IE2 plasmid. 
After 48 hours, cells were cross-linked and chromatin immunoprecipitations were 
performed using the indicated antibody. Primers to UL54-CAT were used in Real Time 
PCR analysis to detect the UL54 promoter as described in Materials and Methods. 
Background levels of an isotype match control were below the level of detection. Real 
time analysis was performed in duplicate and DNA levels were expressed as mean ± SD. 
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Recruitment of Basal Transcription Machinery to the UL54 Promoter 
Since our previous studies have shown that mutated IE2 is unable to activate the 
UL54 promoter, we sought to determine whether the basal transcription machinery was 
recruited to the UL54 promoter in the presence of mutated IE2 using ChIP assays. As 
shown in Fig. 26, neither mutation in IE2 had an effect on RNA polymerase II 
recruitment. These results suggest that IE2 recruitment to the UL54 may not be 
important for recruitment of the RNA polymerase II and IE2 may therefore function 
downstream of RNA polymerase II recruitment. 
Discussion 
IE2 possesses several functional properties that facilitate transcriptional regulation 
of viral promoters during infection (3). First, IE2 has the potential to bind directly to 
DNA through specific sites on promoter regions, such as the cis repression sequence (2, 
18, 48, 121, 122). Second, IE2 is able to interact with members of the basal transcription 
machinery such as TBP or RNA polymerase II (37, 48, 76, 90, 99, 124, 151). Third, IE2 
is able to interact with cellular transcription factors at the promoter, such as SP1 or ATF 
(17, 22, 58, 127). Last, IE2 is able to work in cooperation with other viral proteins such 
as IE1 or the pp71 tegument protein (4, 12, 21, 75, 84, 134, 137). Research is still 
unclear regarding which of the aforementioned properties are required for regulation of 
individual promoters. 
The UL54 promoter encodes the viral DNA polymerase and is essential for virus 
replication (102). However, our understanding of regulation of this promoter in the 
context of a virus infection is limited. Transient assays suggest the IR1 element is 
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Recruitment of RNAPII to UL54 Promoter 
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FIG. 26. Recruitment of RNA Polymerase II to the UL54 promoter in vitro. HeLa 
cells were transfected with 80 [ig of IE2 or mutant IE2 plasmid. After 48 hours, cells 
were cross-linked and chromatin immunoprecipitations were performed using the 
indicated antibody. Primers to UL54-CAT were used in Real Time PCR analysis to 
detect the UL54 promoter as described in Materials and Methods. Background levels of 
an isotype match control were below the level of detection. Real time analysis was 
performed in duplicate and DNA levels were expressed as mean ± SD. 
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required for UL54 activation by the MIE and UL112-113 gene products (59). This 
suggests that these viral proteins may interact with or form a complex with the SP1 
cellular transcription factor found to bind to the IR1 binding site. Mutagenesis of this 
region in HCMV recombinant virus indicates that this region of UL54 is critical at early 
(between 15-24 hours post infection), but not late times (72-96 hours post infection), in 
infection (59). Studies using a recombinant virus mutated in the putative ATF-1 binding 
site reveals a role for ATF in UL54 promoter activation at both early late times in 
infection (61). Mutagenesis is this region reduced UL54 activation significantly at both 
early and late times in infection. 
IE2 interactions with cellular transcription factors may also facilitate 
transactivation of the UL54 promoter. IE2 is able to bind the TBP and RNA polymerase 
II (43, 44, 57, 58). IE2 is also able to interact with the SP1 and ATF-1 general 
transcription factors. Last, IE2 binds histone modifiers such as HDAC2 to regulate 
transcription (98). However, these interactions have not been demonstrated at the UL54 
promoter either during transient transfections or viral infections. 
IE2-TBP Protein Interaction Inhibited by Mutation at Tyrosine 544 in IE2 
One mechanism IE2 utilizes to regulate early gene promoter is through 
interactions with members of the basal transcription machinery. At the UL54 promoter, 
transient transfection studies suggest IE2 acts as a bridge between the SP1 transcription 
factor and TBP. To determine if mutations in IE2 disrupt interactions with TBP, GST-
pulldowns were performed using S-labeled IE2 protein. As shown in Fig. 24, mutations 
in IE2 at amino acid 544 results in a loss of this interaction at the UL54 promoter. The 
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mutation at amino acid 535 did not disrupt this interaction with TBP in vitro. 
Although the TBP interaction domain of IE2, does not map to this amino acid 544 
of IE2, studies suggest that dimerization of IE2 may be important for IE2-TBP 
interactions (127). Since amino acid 544 does overlap the dimerization domain of IE2, it 
is possible that this mutation may inhibit IE2 dimerization. Future studies will assess the 
ability of mutated IE2 to dimerize. 
It is interesting that although the mutations in IE2 at 535 and 544 have similar 
phenotypes of transcriptional regulation, the functional properties of transcriptional 
regulation differ. These results confirm the hypothesis that the IE2 protein may have 
more than one property required for transcriptional regulation of the UL54 promoter. In 
addition to regulating UL54 expression through a direct interaction with TBP, studies 
reveal that IE2 may be able to bind cellular transcription factors, such as SP1 or ATF, 
interact with viral proteins, and/or sequester repressors of the UL54 promoter, such as 
HDAC2 (98). It is possible that the mutations at 535 and 544 may disrupt one or more of 
these mechanisms. Future studies will assess additional IE2-protein interaction which 
may be disrupted by these mutations. In addition, the functional IE2 properties have been 
addressed in vitro within this study. Therefore, it is possible that other viral proteins 
present during HCMV infection may influence the ability of IE2 to interact with proteins 
at the promoter. To more closely uncover functional properties required for regulation 
during infection, future studies should be performed using HCMV BACs. 
Mutations in IE2 Disrupt IE2 recruitment to the UL54 Promoter 
Previous studies indicate that the MIE proteins enhance transcription of the UL54 
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promoter during transient transfections (134). However, it is unclear whether this 
regulation is mediated by IE2 recruitment to the UL54 promoter or through IE2-mediated 
regulation of cellular factors. ChIP assays demonstrate that wildtype IE2 is recruited to 
the UL54 promoter through either direct or indirect interactions at the promoter. 
However, mutagenesis of IE2 at amino acids Pro 535 and Tyr 544 prevent recruitment of 
IE2 to the UL54 promoter. These results are consistent with data demonstrating that a 
double mutation at Pro 535 and Tyr 537 prevents recruitment of IE2 to the UL4 early 
promoter. It is possible that these mutations disrupt the ability of IE2 to interact with 
another viral or cellular factor required for promoter regulation. 
It is difficult to draw a definitive conclusion regarding the mutation at Proline 535 
due to the differences in transcriptional regulation in transient transfections and in the 
context of the genome. While the loss of IE2 recruitment is consistent with inhibition of 
UL54 activation in vitro, this observation is not seen in the context of the viral infection. 
One possible explanation is that other viral proteins may be able to compensate for an 
inability of IE2 to bind the UL54 promoter in the context of a viral infection. In contrast, 
the mutation at 544 may have a more lethal phenotype which cannot be compensated for. 
Future studies of IE2 recruitment in the context of a viral infection will help confirm the 
functional properties of IE2 in transcriptional regulation during virus infection 
RNA polymerase II recruitment to the UL54 is Independent on IE2 Recruitment 
We have shown in Chapter 3 and 4 that mutations in IE2 disrupt transcriptional 
activation of the UL54 promoter in transient assays and/or in the context of the viral 
genome. Due to this loss of UL54 transactivation, we hypothesized that RNA 
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polymerase II would not be recruited to the UL54 promoter in the presence of mutated 
IE2. In addition, previous studies suggest that the IE2 protein may stabilize and/or 
recruitment TBP and RNA polymerase II to the UL54 promoter (59, 62). Interestingly, 
mutations in the IE2 protein did not alter recruitment of the RNA polymerase II to the 
promoter region. In addition, RNA polymerase II is recruited even in the absence of IE2 
expression. Although these results are paradoxical, it is not surprising since the double 
mutation described previously did not alter recruitment of TBP or RNA polymerase II to 
the early gene promoters tested (105). Similarly, our data suggests that IE2 recruitment 
to the UL54 promoter is not required for RNA polymerase II recruitment. However, 
since our data demonstrates that these mutations do alter transcriptional activation of IE2, 
it is likely that mutations at 535 and 544 disrupt other potential mechanism(s) of IE2-
mediated transactivation, such as sequestering repressors of UL54 or altering 
transcriptional regulation following the formation of the pre-initiation complex. 
Summary 
Our analysis of mutations in IE2 at amino acid 535 and 544 has begun narrowing 
down functional properties of IE2 required for transcriptional regulation of the UL54 
promoter. For example, the mutation at amino acid 544, but not 535, impairs IE2-TBP 
interactions in vitro. Similarly, HCMV BACs with mutations in IE2 at amino acid 544, 
but not 535, impair UL54 activation. These studies suggest that IE2-TBP interaction may 
be important in UL54 transcriptional regulation in the context of HCMV infection. In 
addition, mutations at both 535 and 544 disrupt IE2 recruitment to the UL54 promoter, 
suggesting IE2 recruitment is not important for UL54 promoter activation. This 
I l l 
hypothesis is further supported by the fact that RNA polymerase II is recruited to the 
UL54 promoter regardless of whether IE2 is recruited. However, additional studies will 
be required to pinpoint the exact functional mechanism(s) disrupted by mutations in IE2 
to begin identifying functional properties required for promoter regulation. More 
specifically, future studies should assess the ability of mutated IE2 protein to interact 
with viral and cellular factors, as well as DNA, in vitro and in the context of a viral 
infection. 
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CHAPTER VI 
CONCLUSIONS 
The IE2 protein plays a key role in transcriptional regulation of early gene 
promoters by functioning to recruit cellular and viral transcription factors as well as 
members of the basal transcription machinery. More importantly, current research 
suggests that individual promoters are regulated by distinct transcriptional regulatory 
properties. The studies described in this dissertation have three primary aims (1) 
characterization of IE2 functional domains involved in transcriptional regulation during 
transient transfections (2) characterization of IE2 functional domains important in viral 
replication and transcriptional regulation during infection, and (3) identification of IE2 
transcriptional regulatory properties which may be inhibited in IE2 mutations resulting in 
impaired virus replication and transcriptional regulation. 
In this study, we have shown that mutations in the C-terminus of IE2, between 
amino acid 535 and 545, prevent transcriptional regulation of essential viral promoters 
(UL54, UL122-123, and UL112-113) in transient transfections. In addition, these 
mutations alter IE2 mRNA or protein expression. Previous studies have shown that 
biological processes characterized in vitro may not be reproducible in vivo. In addition, it 
is difficult to generate viable virus with a mutation in an essential gene. To overcome 
this obstacle and assess the effects of the mutations in IE2 on virus replication, 
recombinant viruses were generated using bacterial artificial chromosomes (BAC). 
Mutations in amino acids 535 and 544 resulted in nonviable recombinant virus when 
compared to wildtype. This is most likely due to an inability to differentially activate 
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viral promoters essential for virus replication, including UL112-113 and/or UL54, as 
demonstrated using recombinant HCMV BACs. Mutations at Proline 535 or Tyrosine 
544 impaired UL112-113 and/or UL54 early gene activation in the context of the viral 
genome. Thus, we are able to conclude that mutations in the C-terminus of IE2 result in 
loss of early gene activation of essential genes and prevent virus replication. 
Both of our mutations in IE2 of HCMV BACs resulted in a loss of MIE 
repression. However, since we saw differential regulation of early gene promoters with 
different mutations in IE2, our results support the hypothesis that both independent and 
overlapping IE2 functional domains of IE2 are required for regulation of individual viral 
promoter. For example, the autoregulatory domain of IE2 may overlap a functional 
domain of IE2 important for activation of the UL112-113 promoter, but not the UL54 
promoter. 
Potential mechanism(s) by which IE2 is able to regulate viral promoters include 
(1) interactions with transcription factors, (2) interactions with members of the basal 
transcription machinery, (3) binding directly to DNA, (4) functioning in cooperation with 
viral proteins, and/or (5) sequestering of cellular repressors. In this study, we begin 
narrowing down functional properties of IE2 important in UL54 activation in transient 
assays. We demonstrate that IE2 is recruited to the UL54 promoter during transient 
transfection and suggest IE2 recruitment may not be required for RNA polymerase II 
recruitment. We also show TBP-IE2 interactions are disrupted by mutations in IE2 
suggesting another mechanism of transcriptional regulation that may be required for 
UL54 promoter activation. 
Future studies will expand of analysis of IE2 functional properties and identify 
114 
properties of IE2 impaired by IE2 mutagenesis both in vitro and during virus infection. 
Specifically, future studies will begin to assess additional functional properties of IE2, 
such as interactions with histone modifying enzymes and evaluate these properties in the 
context of the virus in order to gain a more biologically relevant assessment. 
Furthermore, to gain a better understanding of which functional properties of IE2 are 
required for transcriptional regulation of early gene promoters a more global assess of 
gene regulation would be used. Microarray analysis of HCMV gene expression would 
allow us to assess which functional properties of IE2 are required for transcriptional 
regulation of individual promoters. Last, further analysis of other HCMV mutated BACs, 
such as a Threonine 541 mutation in IE2, will further strengthen the hypothesis that IE2 
differentially regulates individual promoters based on independent functional properties. 
Overall, these result concluded in the dissertation will be significant in gaining a 
better understanding of HCMV replication and regulation of viral genes essential for 
virus replication. This will be important in the development of novel therapies for CMV 
treatment and prevention. 
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